Alternative splicing and related RNA binding proteins in human health and disease

Abstract

Alternative splicing (AS) serves as a pivotal mechanism in transcriptional regulation, engendering transcript diversity, and modifications in protein structure and functionality. Across varying tissues, developmental stages, or under specific conditions, AS gives rise to distinct splice isoforms. This implies that these isoforms possess unique temporal and spatial roles, thereby associating AS with standard biological activities and diseases. Among these, AS-related RNA-binding proteins (RBPs) play an instrumental role in regulating alternative splicing events. Under physiological conditions, the diversity of proteins mediated by AS influences the structure, function, interaction, and localization of proteins, thereby participating in the differentiation and development of an array of tissues and organs. Under pathological conditions, alterations in AS are linked with various diseases, particularly cancer. These changes can lead to modifications in gene splicing patterns, culminating in changes or loss of protein functionality. For instance, in cancer, abnormalities in AS and RBPs may result in aberrant expression of cancer-associated genes, thereby promoting the onset and progression of tumors. AS and RBPs are also associated with numerous neurodegenerative diseases and autoimmune diseases. Consequently, the study of AS across different tissues holds significant value. This review provides a detailed account of the recent advancements in the study of alternative splicing and AS-related RNA-binding proteins in tissue development and diseases, which aids in deepening the understanding of gene expression complexity and offers new insights and methodologies for precision medicine.

References 511

1. 1.

   Ule J, Blencowe BJ. Alternative splicing regulatory networks: functions, mechanisms, and evolution. Mol. Cell. 2019;76:329-345.

   Not in our library10.1016/j.molcel.2019.09.017

2. 2.

   Khan MR, Wellinger RJ, Laurent B. Exploring the alternative splicing of long noncoding RNAs. Trends Genet. 2021;37:695-698.

   Not in our library10.1016/j.tig.2021.03.010

3. 3.

   Rogers SO. Integrated evolution of ribosomal RNAs, introns, and intron nurseries. Genetica. 2019;147:103-119.

   Not in our library10.1007/s10709-018-0050-y

4. 4.

   Marasco LE, Kornblihtt AR. The physiology of alternative splicing. Nat. Rev. Mol. Cell Biol. 2023;24:242-254.

   Not in our library10.1038/s41580-022-00545-z

5. 5.
   RNA modifications in brain tumorigenesis · 2020

   Not checked
6. 6.

   Hoyos LE, Abdel-Wahab O. Cancer-specific splicing changes and the potential for splicing-derived neoantigens. Cancer Cell. 2018;34:181-183.

   Not in our library10.1016/j.ccell.2018.07.008

7. 7.

   Wang S, Sun Z, Lei Z, Zhang HT. RNA-binding proteins and cancer metastasis. Semin. Cancer Biol. 2022;86:748-768.

   Not in our library10.1016/j.semcancer.2022.03.018

8. 8.

   Choi S, Cho N, Kim KK. The implications of alternative pre-mRNA splicing in cell signal transduction. Exp. Mol. Med. 2023;55:755-766.

   Not in our library10.1038/s12276-023-00981-7

9. 9.
   RNA-binding proteins in tumor progression · 2020

   No notice
10. 10.

    Swanson M, et al. Dynamic mutations and RNA mis-splicing in disease. Eur. J. Hum. Genet. 2019;27:1050-1050.

    Not in our library

11. 11.

    Scotti MM, Swanson MS. RNA mis-splicing in disease. Nat. Rev. Genet. 2016;17:19-32.

    Not in our library10.1038/nrg.2015.3

12. 12.

    Saldi T, Riemondy K, Erickson B, Bentley DL. Alternative RNA structures formed during transcription depend on elongation rate and modify RNA processing. Mol. Cell. 2021;81:1789-1801.e1785.

    Not in our library10.1016/j.molcel.2021.01.040

13. 13.

    Wilkinson ME, Charenton C, Nagai K. RNA splicing by the spliceosome. Annu. Rev. Biochem. 2020;89:359-388.

    Not in our library10.1146/annurev-biochem-091719-064225

14. 14.
    A large-scale binding and functional map of human RNA-binding proteins · 2020

    Corrected
15. 15.

    Van Nostrand EL, et al. Robust transcriptome-wide discovery of RNA-binding protein binding sites with enhanced CLIP (eCLIP). Nat. Methods. 2016;13:508-514.

    Not in our library10.1038/nmeth.3810

16. 16.

    Jankowsky E, Harris ME. Specificity and nonspecificity in RNA-protein interactions. Nat. Rev. Mol. Cell Biol. 2015;16:533-544.

    Not in our library10.1038/nrm4032

17. 17.

    Erkelenz S, et al. Position-dependent splicing activation and repression by SR and hnRNP proteins rely on common mechanisms. Rna. 2013;19:96-102.

    Not in our library10.1261/rna.037044.112

18. 18.

    Pereira B, Billaud M, Almeida R. RNA-binding proteins in cancer: old players and new actors. Trends Cancer. 2017;3:506-528.

    Not in our library10.1016/j.trecan.2017.05.003

19. 19.

    Fica SM, et al. RNA catalyses nuclear pre-mRNA splicing. Nature. 2013;503:229-234.

    Not in our library10.1038/nature12734

20. 20.

    Wahl MC, Will CL, Luhrmann R. The spliceosome: design principles of a dynamic RNP machine. Cell. 2009;136:701-718.

    Not in our library10.1016/j.cell.2009.02.009

21. 21.

    Ying Y, et al. Splicing activation by Rbfox requires self-aggregation through its tyrosine-rich domain. Cell. 2017;170:312-323.e310.

    Not in our library10.1016/j.cell.2017.06.022

22. 22.

    Padgett RA. New connections between splicing and human disease. Trends Genet. 2012;28:147-154.

    Not in our library10.1016/j.tig.2012.01.001

23. 23.

    Wright CJ, Smith CWJ, Jiggins CD. Alternative splicing as a source of phenotypic diversity. Nat. Rev. Genet. 2022;23:697-710.

    Not in our library10.1038/s41576-022-00514-4

24. 24.

    Wan R, Bai R, Zhan X, Shi Y. How is precursor messenger RNA spliced by the spliceosome? Annu. Rev. Biochem. 2020;89:333-358.

    Not in our library10.1146/annurev-biochem-013118-111024

25. 25.

    Tian B, Manley JL. Alternative polyadenylation of mRNA precursors. Nat. Rev. Mol. Cell Biol. 2017;18:18-30.

    Not in our library10.1038/nrm.2016.116

26. 26.

    Pal S, Gupta R, Davuluri RV. Alternative transcription and alternative splicing in cancer. Pharmacol. Ther. 2012;136:283-294.

    Not in our library10.1016/j.pharmthera.2012.08.005

27. 27.

    Urbanski LM, Leclair N, Anczukow O. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. Wires Rna. 2018;9:e1476.

    Not in our library10.1002/wrna.1476

28. 28.

    Liu MM, Zack DJ. Alternative splicing and retinal degeneration. Clin. Genet. 2013;84:142-149.

    Not in our library10.1111/cge.12181

29. 29.

    Matera AG, Wang ZF. A day in the life of the spliceosome (vol 15, pg 108, 2014). Nat. Rev. Mol. Cell Biol. 2014;15:108-121.

    Not in our library10.1038/nrm3742

30. 30.

    Zhou HL, Luo G, Wise JA, Lou H. Regulation of alternative splicing by local histone modifications: potential roles for RNA-guided mechanisms. Nucleic Acids Res. 2014;42:701-713.

    Not in our library10.1093/nar/gkt875

31. 31.

    Do HTT, Shanak S, Barghash A, Helms V. Differential exon usage of developmental genes is associated with deregulated epigenetic marks. Sci. Rep. 2023;13:12256.

    Not in our library10.1038/s41598-023-38879-z

32. 32.

    El-Samad H. Biological feedback control—respect the loops. Cell Syst. 2021;12:477-487.

    Not in our library10.1016/j.cels.2021.05.004

33. 33.

    Pullmann R, et al. Analysis of turnover and translation regulatory RNA-binding protein expression through binding to cognate mRNAs. Mol. Cell Biol. 2007;27:6265-6278.

    Not in our library10.1128/mcb.00500-07

34. 34.

    Ding F, et al. Dynamics and functional roles of splicing factor autoregulation. Cell Rep. 2022;39:110985.

    Not in our library10.1016/j.celrep.2022.110985

35. 35.

    Zhou KI, et al. Regulation of co-transcriptional pre-mRNA splicing by m(6)A through the low-complexity protein hnRNPG. Mol. Cell. 2019;76:70-81.e79.

    Not in our library10.1016/j.molcel.2019.07.005

36. 36.

    Zhang X, et al. An atomic structure of the human spliceosome. Cell. 2017;169:918-929.e914.

    Not in our library10.1016/j.cell.2017.04.033

37. 37.

    Bertram K, et al. Cryo-EM structure of a pre-catalytic human spliceosome primed for activation. Cell. 2017;170:701-713.e711.

    Not in our library10.1016/j.cell.2017.07.011

38. 38.

    Venables JP, et al. RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues. Mol. Cell Biol. 2013;33:396-405.

    Not in our library10.1128/mcb.01174-12

39. 39.

    Brosseau JP, et al. Tumor microenvironment-associated modifications of alternative splicing. Rna. 2014;20:189-201.

    Not in our library10.1261/rna.042168.113

40. 40.

    Lambert N, et al. RNA Bind-n-Seq: quantitative assessment of the sequence and structural binding specificity of RNA binding proteins. Mol. Cell. 2014;54:887-900.

    Not in our library10.1016/j.molcel.2014.04.016

41. 41.

    Jangi M, Boutz PL, Paul P, Sharp PA. Rbfox2 controls autoregulation in RNA-binding protein networks. Genes Dev. 2014;28:637-651.

    Not in our library10.1101/gad.235770.113

42. 42.

    Huang SC, et al. RBFOX2 promotes protein 4.1R exon 16 selection via U1 snRNP recruitment. Mol. Cell Biol. 2012;32:513-526.

    Not in our library10.1128/mcb.06423-11

43. 43.

    Gu M, et al. Suppression of RBFox2 by multiple MiRNAs in pressure overload-induced heart failure. Int. J. Mol. Sci. 2023;24:1283.

    Not in our library10.3390/ijms24021283

44. 44.

    Damianov A, et al. Rbfox proteins regulate splicing as part of a large multiprotein complex LASR. Cell. 2016;165:606-619.

    Not in our library10.1016/j.cell.2016.03.040

45. 45.

    Zhou D, Couture S, Scott MS, Abou Elela S. RBFOX2 alters splicing outcome in distinct binding modes with multiple protein partners. Nucleic Acids Res. 2021;49:8370-8383.

    Not in our library10.1093/nar/gkab595

46. 46.

    Castella S, et al. Ilf3 and NF90 functions in RNA biology. Wires Rna. 2015;6:243-256.

    Not in our library10.1002/wrna.1270

47. 47.
    ZFR coordinates crosstalk between RNA decay and transcription in innate immunity · 2018

    Not checked
48. 48.

    Haque N, Will A, Cook AG, Hogg JR. A network of DZF proteins controls alternative splicing regulation and fidelity. Nucleic Acids Res. 2023;51:6411-6429.

    Not in our library10.1093/nar/gkad351

49. 49.

    Guo J, Jia J, Jia R. PTBP1 and PTBP2 impaired autoregulation of SRSF3 in cancer cells. Sci. Rep. 2015;5:14548.

    Not in our library10.1038/srep14548

50. 50.

    Hu X, et al. The RNA-binding protein AKAP8 suppresses tumor metastasis by antagonizing EMT-associated alternative splicing. Nat. Commun. 2020;11:486.

    Not in our library10.1038/s41467-020-14304-1

51. 51.

    Ye R, et al. Capture RIC-seq reveals positional rules of PTBP1-associated RNA loops in splicing regulation. Mol. Cell. 2023;83:1311-1327.e1317.

    Not in our library10.1016/j.molcel.2023.03.001

52. 52.

    Mullari M, et al. Characterising the RNA-binding protein atlas of the mammalian brain uncovers RBM5 misregulation in mouse models of Huntington’s disease. Nat. Commun. 2023;14:4348.

    Not in our library10.1038/s41467-023-39936-x

53. 53.

    Lee FCY, Ule J. Advances in CLIP technologies for studies of protein-RNA interactions. Mol. Cell. 2018;69:354-369.

    Not in our library10.1016/j.molcel.2018.01.005

54. 54.

    Kristofich J, Nicchitta CV. Signal-noise metrics for RNA binding protein identification reveal broad spectrum protein-RNA interaction frequencies and dynamics. Nat. Commun. 2023;14:5868.

    Not in our library10.1038/s41467-023-41284-9

55. 55.

    Hentze MW, Castello A, Schwarzl T, Preiss T. A brave new world of RNA-binding proteins. Nat. Rev. Mol. Cell Biol. 2018;19:327-341.

    Not in our library10.1038/nrm.2017.130

56. 56.

    Vaquero-Garcia J, et al. RNA splicing analysis using heterogeneous and large RNA-seq datasets. Nat. Commun. 2023;14:1230.

    Not in our library10.1038/s41467-023-36585-y

57. 57.

    Gonatopoulos-Pournatzis T, et al. Genome-wide CRISPR-Cas9 interrogation of splicing networks reveals a mechanism for recognition of autism-misregulated neuronal microexons. Mol. Cell. 2018;72:510-524.e512.

    Not in our library10.1016/j.molcel.2018.10.008

58. 58.

    Wagner N, et al. Aberrant splicing prediction across human tissues. Nat. Genet. 2023;55:861-870.

    Not in our library10.1038/s41588-023-01373-3

59. 59.

    Ramanathan M, Porter DF, Khavari PA. Methods to study RNA-protein interactions. Nat. Methods. 2019;16:351-351.

    Not in our library10.1038/s41592-019-0366-2

60. 60.

    Li YF, et al. CBRPP: a new RNA-centric method to study RNA-protein interactions. Rna Biol. 2021;18:1608-1621.

    Not in our library10.1080/15476286.2021.1873620

61. 61.

    Sciarrillo R, et al. The role of alternative splicing in cancer: from oncogenesis to drug resistance. Drug Resist. Update. 2020;53:100728.

    Not in our library10.1016/j.drup.2020.100728

62. 62.

    Hu Y, Wang K, Li MY. Detecting differential alternative splicing events in scRNA-seq with or without unique molecular identifiers. PLoS Comput. Biol. 2020;16:e1007925.

    Not in our library10.1371/journal.pcbi.1007925

63. 63.

    Wan Y, Larson DR. Splicing heterogeneity: separating signal from noise. Genome Biol. 2018;19:86.

    Not in our library10.1186/s13059-018-1467-4

64. 64.

    Bao SY, Moakley DF, Zhang CL. The splicing code goes deep. Cell. 2019;176:414-416.

    Not in our library10.1016/j.cell.2019.01.013

65. 65.

    Jaganathan K, et al. Predicting splicing from primary sequence with deep learning. Cell. 2019;176:535-548.e524.

    Not in our library10.1016/j.cell.2018.12.015

66. 66.

    Baeza-Centurion P, et al. Combinatorial genetics reveals a scaling law for the effects of mutations on splicing. Cell. 2019;176:549-563.e523.

    Not in our library10.1016/j.cell.2018.12.010

67. 67.

    Chen H, et al. DIFFUSE: predicting isoform functions from sequences and expression profiles via deep learning. Bioinformatics. 2019;35:I284-I294.

    Not in our library10.1093/bioinformatics/btz367

68. 68.

    Nag S, Goswami B, Das Mandal S, Ray PS. Cooperation and competition by RNA-binding proteins in cancer. Semin Cancer Biol. 2022;86:286-297.

    Not in our library10.1016/j.semcancer.2022.02.023

69. 69.
    Genetic control of RNA splicing and its distinct role in complex trait variation · 2022

    No notice
70. 70.

    Fu XD, Ares M. Context-dependent control of alternative splicing by RNA-binding proteins. Nat. Rev. Genet. 2014;15:689-701.

    Not in our library10.1038/nrg3778

71. 71.

    Liu Z, et al. Manual correction of genome annotation improved alternative splicing identification of Artemisia annua. Planta. 2023;258:83.

    Not in our library10.1007/s00425-023-04237-6

72. 72.

    Kalsotra A, et al. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc. Natl. Acad. Sci. USA. 2008;105:20333-20338.

    Not in our library10.1073/pnas.0809045105

73. 73.

    Yang JB, et al. CLOCK interacts with RANBP9 and is involved in alternative splicing in spermatogenesis. Gene. 2018;642:199-204.

    Not in our library10.1016/j.gene.2017.11.007

74. 74.

    Cheng CY, Wong EW, Yan HH, Mruk DD. Regulation of spermatogenesis in the microenvironment of the seminiferous epithelium: new insights and advances. Mol. Cell Endocrinol. 2010;315:49-56.

    Not in our library10.1016/j.mce.2009.08.004

75. 75.

    Schmid R, et al. The splicing landscape is globally reprogrammed during male meiosis. Nucleic Acids Res. 2013;41:10170-10184.

    Not in our library10.1093/nar/gkt811

76. 76.
    Single-cell RNA-seq uncovers dynamic processes and critical regulators in mouse spermatogenesis · 2018

    No notice
77. 77.
    Ptbp2 Controls an Alternative Splicing Network Required for Cell Communication during Spermatogenesis · 2017

    Not checked
78. 78.

    Feng SL, et al. hnRNPH1 recruits PTBP2 and SRSF3 to modulate alternative splicing in germ cells. Nat. Commun. 2022;13:3588.

    Not in our library10.1038/s41467-022-31364-7

79. 79.

    Qin J, et al. Bud31-mediated alternative splicing is required for spermatogonial stem cell self-renewal and differentiation. Cell Death Differ. 2023;30:184-194.

    Not in our library10.1038/s41418-022-01057-1

80. 80.

    Liu W, et al. SRSF10 is essential for progenitor spermatogonia expansion by regulating alternative splicing. eLife. 2022;11:e78211.

    Not in our library10.7554/elife.78211

81. 81.
    DDX5 plays essential transcriptional and post-transcriptional roles in the maintenance and function of spermatogonia · 2019

    No notice
82. 82.

    Sada A, Suzuki A, Suzuki H, Saga Y. The RNA-binding protein NANOS2 is required to maintain murine spermatogonial stem cells. Science. 2009;325:1394-1398.

    Not in our library10.1126/science.1172645

83. 83.

    Soni K, et al. Structural basis for specific RNA recognition by the alternative splicing factor RBM5. Nat. Commun. 2023;14:4233.

    Not in our library10.1038/s41467-023-39961-w

84. 84.

    Song H, Wang L, Chen D, Li F. The function of pre-mRNA alternative splicing in mammal spermatogenesis. Int. J. Biol. Sci. 2020;16:38-48.

    Not in our library10.7150/ijbs.34422

85. 85.
    Identification and characterization of circular RNAs in Qinchuan cattle testis · 2018

    Not checked
86. 86.

    Zhou F, Chen W, Jiang Y, He Z. Regulation of long non-coding RNAs and circular RNAs in spermatogonial stem cells. Reproduction. 2019;158:R15-R25.

    Not in our library10.1530/rep-18-0517

87. 87.

    Schieweck R, Ninkovic J, Kiebler MA. Rna-binding proteins balance brain function in health and disease. Physiol. Rev. 2021;101:1309-1370.

    Not in our library10.1152/physrev.00047.2019

88. 88.

    Nikom D, Zheng S. Alternative splicing in neurodegenerative disease and the promise of RNA therapies. Nat. Rev. Neurosci. 2023;24:457-473.

    Not in our library10.1038/s41583-023-00717-6

89. 89.

    Salehi S, et al. Cytosolic Ptbp2 modulates axon growth in motoneurons through axonal localization and translation of Hnrnpr. Nat. Commun. 2023;14:4158.

    Not in our library10.1038/s41467-023-39787-6

90. 90.

    Licatalosi DD, et al. Ptbp2 represses adult-specific splicing to regulate the generation of neuronal precursors in the embryonic brain. Genes Dev. 2012;26:1626-1642.

    Not in our library10.1101/gad.191338.112

91. 91.

    Zhang X, et al. Cell-type-specific alternative splicing governs cell fate in the developing cerebral cortex. Cell. 2016;166:1147-1162.e1115.

    Not in our library10.1016/j.cell.2016.07.025

92. 92.

    Hayakawa-Yano Y, Yano M. An RNA switch of a large exon of ninein is regulated by the neural stem cell specific-RNA binding protein, Qki5. Int. J. Mol. Sci. 2019;20:1010.

    Not in our library10.3390/ijms20051010

93. 93.

    Quesnel-Vallieres M, Irimia M, Cordes SP, Blencowe BJ. Essential roles for the splicing regulator nSR100/SRRM4 during nervous system development. Gene Dev. 2015;29:746-759.

    Not in our library10.1101/gad.256115.114

94. 94.

    Zheng S. Alternative splicing programming of axon formation. Wiley Interdiscip. Rev. RNA. 2020;11:e1585.

    Not in our library10.1002/wrna.1585

95. 95.

    Kim JH, et al. SON drives oncogenic RNA splicing in glioblastoma by regulating PTBP1/PTBP2 switching and RBFOX2 activity. Nat. Commun. 2021;12:5551.

    Not in our library10.1038/s41467-021-25892-x

96. 96.

    Vuong JK, et al. PTBP1 and PTBP2 serve both specific and redundant functions in neuronal pre-mRNA splicing. Cell Rep. 2016;17:2766-2775.

    Not in our library10.1016/j.celrep.2016.11.034

97. 97.
    RNA-binding protein signaling in adult neurogenesis · 2022

    Not checked
98. 98.

    Qian H, et al. Reversing a model of Parkinson’s disease with in situ converted nigral neurons. Nature. 2020;582:550-556.

    Not in our library10.1038/s41586-020-2388-4

99. 99.
    Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson’s disease · 2022

    Not checked
100. 100.

     Hoang T, et al. Genetic loss of function of Ptbp1 does not induce glia-to-neuron conversion in retina. Cell Rep. 2022;39:110849.

     Not in our library10.1016/j.celrep.2022.110849

101. 101.

     Villate O, et al. Nova1 is a master regulator of alternative splicing in pancreatic beta cells. Nucleic Acids Res. 2014;42:11818-11830.

     Not in our library10.1093/nar/gku861

102. 102.

     Lin JC, et al. RBM4 promotes pancreas cell differentiation and insulin expression. Mol. Cell Biol. 2013;33:319-327.

     Not in our library10.1128/mcb.01266-12

103. 103.

     Du X, et al. Downregulated liver-elevated long intergenic noncoding RNA (LINC02428) is a tumor suppressor that blocks KDM5B/IGF2BP1 positive feedback loop in hepatocellular carcinoma. Cell Death Dis. 2023;14:301.

     Not in our library10.1038/s41419-023-05831-y

104. 104.

     Suzuki T, et al. Regulation of fetal genes by transitions among RNA-binding proteins during liver development. Int. J. Mol. Sci. 2020;21:9319.

     Not in our library10.3390/ijms21239319

105. 105.

     Mobin MB, et al. The RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation. Nat. Commun. 2016;7:12848.

     Not in our library10.1038/ncomms12848

106. 106.

     Paterson HAB, et al. Liver RBFOX2 regulates cholesterol homeostasis via Scarb1 alternative splicing in mice. Nat. Metab. 2022;4:1812-1829.

     Not in our library10.1038/s42255-022-00681-y

107. 107.

     Vatandaslar H, et al. In vivo PAR-CLIP (viP-CLIP) of liver TIAL1 unveils targets regulating cholesterol synthesis and secretion. Nat. Commun. 2023;14:3386.

     Not in our library10.1038/s41467-023-39135-8

108. 108.

     Osma-Garcia IC, et al. The splicing regulators TIA1 and TIAL1 are required for the expression of the DNA damage repair machinery during B cell lymphopoiesis. Cell Rep. 2022;41:111869.

     Not in our library10.1016/j.celrep.2022.111869

109. 109.
     Splicing factor SRSF1 deficiency in the liver triggers NASH-like pathology and cell death · 2023

     Not checked
110. 110.

     Sen S, Jumaa H, Webster NJG. Splicing factor SRSF3 is crucial for hepatocyte differentiation and metabolic function. Nat. Commun. 2013;4:1336.

     Not in our library10.1038/ncomms2342

111. 111.

     Pihlajamaki J, et al. Expression of the splicing factor gene SFRS10 is reduced in human obesity and contributes to enhanced lipogenesis. Cell Metab. 2011;14:208-218.

     Not in our library10.1016/j.cmet.2011.06.007

112. 112.

     Bhate A, et al. ESRP2 controls an adult splicing programme in hepatocytes to support postnatal liver maturation. Nat. Commun. 2015;6:8768.

     Not in our library10.1038/ncomms9768

113. 113.

     Bangru S, et al. Alternative splicing rewires Hippo signaling pathway in hepatocytes to promote liver regeneration. Nat. Struct. Mol. Biol. 2018;25:928-939.

     Not in our library10.1038/s41594-018-0129-2

114. 114.

     Hyun J, et al. Epithelial splicing regulatory protein 2-mediated alternative splicing reprograms hepatocytes in severe alcoholic hepatitis. J. Clin. Investig. 2020;130:2129-2145.

     Not in our library10.1172/jci132691

115. 115.

     Patel C, et al. Fructose-induced increases in expression of intestinal fructolytic and gluconeogenic genes are regulated by GLUT5 and KHK. Am. J. Physiol.-Reg. Integr. Comp. Physiol. 2015;309:R499-R509.

     Not in our library10.1152/ajpregu.00128.2015

116. 116.
     New Mammalian Glycerol-3-Phosphate Phosphatase: Role in β-Cell, Liver and Adipocyte Metabolism · 2021

     Not checked
117. 117.

     Mirtschink P, Jang C, Arany Z, Krek W. Fructose metabolism, cardiometabolic risk, and the epidemic of coronary artery disease. Eur. Heart J. 2018;39:2497-2505.

     Not in our library10.1093/eurheartj/ehx518

118. 118.

     Li XJ, et al. A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation. Nat. Cell Biol. 2016;18:709-709.

     Not in our library10.1038/ncb3361

119. 119.

     Pecori, R., Di Giorgio, S., Paulo Lorenzo, J. & Nina Papavasiliou, F. Functions and consequences of AID/APOBEC-mediated DNA and RNA deamination. Nat. Rev. Genet.23, 505–518 (2022).

     Not in our library10.1038/s41576-022-00459-8

120. 120.

     Nikolaou KC, et al. The RNA-binding protein A1CF regulates hepatic fructose and glycerol metabolism via alternative RNA splicing. Cell Rep. 2019;29:283-300 e288.

     Not in our library10.1016/j.celrep.2019.08.100

121. 121.

     Chembazhi UV, et al. PTBP1 controls intestinal epithelial regeneration through post-transcriptional regulation of gene expression. Nucleic Acids Res. 2023;51:2397-2414.

     Not in our library10.1093/nar/gkad042

122. 122.

     Jin ZG, Liang F, Yang J, Mei WY. hnRNP I regulates neonatal immune adaptation and prevents colitis and colorectal cancer. PLoS Genet. 2017;13:e1006672.

     Not in our library10.1371/journal.pgen.1006672

123. 123.

     Ergun A, et al. Differential splicing across immune system lineages. Proc. Natl. Acad. Sci. USA. 2013;110:14324-14329.

     Not in our library10.1073/pnas.1311839110

124. 124.

     Alexander DR. The CD45 tyrosine phosphatase: a positive and negative regulator of immune cell function. Semin. Immunol. 2000;12:349-359.

     Not in our library10.1006/smim.2000.0218

125. 125.

     Yabas M, Elliott H, Hoyne GF. The role of alternative splicing in the control of immune homeostasis and cellular differentiation. Int. J. Mol. Sci. 2015;17:3.

     Not in our library10.3390/ijms17010003

126. 126.

     Chang X. RNA-binding protein hnRNPLL as a critical regulator of lymphocyte homeostasis and differentiation. Wiley Interdiscip. Rev. Rna. 2016;7:295-302.

     Not in our library10.1002/wrna.1335

127. 127.

     Liao KC, Garcia-Blanco MA. Role of alternative splicing in regulating host response to viral infection. Cells. 2021;10:1720.

     Not in our library10.3390/cells10071720

128. 128.

     Liu J, Cao X. RBP-RNA interactions in the control of autoimmunity and autoinflammation. Cell Res. 2023;33:97-115.

     Not in our library10.1038/s41422-022-00752-5

129. 129.

     Geng G, et al. PTBP1 is necessary for dendritic cells to regulate T-cell homeostasis and antitumour immunity. Immunology. 2021;163:74-85.

     Not in our library10.1111/imm.13304

130. 130.

     Lau CI, et al. The pioneer transcription factors Foxa1 and Foxa2 regulate alternative RNA splicing during thymocyte positive selection. Development. 2021;148:dev199754.

     Not in our library10.1242/dev.199754

131. 131.

     Cassidy MF, Herbert ZT, Moulton VR. Splicing factor SRSF1 controls distinct molecular programs in regulatory and effector T cells implicated in systemic autoimmune disease. Mol. Immunol. 2022;141:94-103.

     Not in our library10.1016/j.molimm.2021.11.008

132. 132.

     Victora GD, Nussenzweig MC. Germinal centers. Annu. Rev. Immunol. 2022;40:413-442.

     Not in our library10.1146/annurev-immunol-120419-022408

133. 133.

     Monzon-Casanova E, et al. Polypyrimidine tract-binding proteins are essential for B cell development. eLife. 2020;9:e53557.

     Not in our library10.7554/elife.53557

134. 134.

     Monzon-Casanova E, et al. The RNA-binding protein PTBP1 is necessary for B cell selection in germinal centers. Nat. Immunol. 2018;19:267-278.

     Not in our library10.1038/s41590-017-0035-5

135. 135.

     Osma-Garcia IC, et al. The RNA-binding protein HuR is required for maintenance of the germinal centre response. Nat. Commun. 2021;12:6556.

     Not in our library10.1038/s41467-021-26908-2

136. 136.

     Diaz-Munoz MD, et al. The RNA-binding protein HuR is essential for the B cell antibody response. Nat. Immunol. 2015;16:415-425.

     Not in our library10.1038/ni.3115

137. 137.

     Osma-Garcia IC, et al. The RNA binding proteins TIA1 and TIAL1 promote Mcl1 mRNA translation to protect germinal center responses from apoptosis. Cell Mol. Immunol. 2023;20:1063-1076.

     Not in our library10.1038/s41423-023-01063-4

138. 138.

     Sidali A, et al. AU-rich element RNA binding proteins: at the crossroads of post-transcriptional regulation and genome integrity. Int. J. Mol. Sci. 2021;23:96.

     Not in our library10.3390/ijms23010096

139. 139.

     Vikstrom I, et al. Mcl-1 is essential for germinal center formation and B cell memory. Science. 2010;330:1095-1099.

     Not in our library10.1126/science.1191793

140. 140.

     Wagner AR, et al. SRSF6 balances mitochondrial-driven innate immune outcomes through alternative splicing of BAX. eLife. 2022;11:e82244.

     Not in our library10.7554/elife.82244

141. 141.

     de Bruin RG, et al. Quaking promotes monocyte differentiation into pro-atherogenic macrophages by controlling pre-mRNA splicing and gene expression. Nat. Commun. 2016;7:10846.

     Not in our library10.1038/ncomms10846

142. 142.
     The Emerging Roles of the RNA Binding Protein QKI in Cardiovascular Development and Function · 2021

     Not checked
143. 143.

     Giampietro C, et al. The alternative splicing factor Nova2 regulates vascular development and lumen formation. Nat. Commun. 2015;6:8479.

     Not in our library10.1038/ncomms9479

144. 144.
     A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing · 2019

     Not checked
145. 145.

     Belloni E, et al. Gene expression profiles controlled by the alternative splicing factor Nova2 in endothelial cells. Cells. 2019;8:1498.

     Not in our library10.3390/cells8121498

146. 146.

     Baek S, et al. The alternative splicing regulator Nova2 constrains vascular Erk signaling to limit specification of the lymphatic lineage. Dev. Cell. 2019;49:279-292.e275.

     Not in our library10.1016/j.devcel.2019.03.017

147. 147.

     Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer. 2009;9:785-797.

     Not in our library10.1038/nrc2696

148. 148.

     Pradella D, et al. A ligand-insensitive UNC5B splicing isoform regulates angiogenesis by promoting apoptosis. Nat. Commun. 2021;12:4872.

     Not in our library10.1038/s41467-021-24998-6

149. 149.

     Luo Y, et al. KRAS mutant-driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer. J. Clin. Investig. 2022;132:e157644.

     Not in our library10.1172/jci157644

150. 150.

     Xia XD, et al. Myocardin: a novel player in atherosclerosis. Atherosclerosis. 2017;257:266-278.

     Not in our library10.1016/j.atherosclerosis.2016.12.002

151. 151.

     van der Veer EP, et al. Quaking, an RNA-binding protein, is a critical regulator of vascular smooth muscle cell phenotype. Circ. Res. 2013;113:1065-1075.

     Not in our library10.1161/circresaha.113.301302

152. 152.

     McCann KL, Baserga SJ. Genetics. Mysterious ribosomopathies. Science. 2013;341:849-850.

     Not in our library10.1126/science.1244156

153. 153.

     Hou VC, et al. Decrease in hnRNP A/B expression during erythropoiesis mediates a pre-mRNA splicing switch. EMBO J. 2002;21:6195-6204.

     Not in our library10.1093/emboj/cdf625

154. 154.

     Huang SC, et al. Protein 4.1R exon 16 3’ splice site activation requires coordination among TIA1, Pcbp1, and RBM39 during terminal erythropoiesis. Mol. Cell Biol. 2017;37:e00446-16.

     Not in our library10.1128/mcb.00446-16

155. 155.

     Alvarez-Dominguez JR, Zhang X, Hu W. Widespread and dynamic translational control of red blood cell development. Blood. 2017;129:619-629.

     Not in our library10.1182/blood-2016-09-741835

156. 156.

     van den Hoogenhof MM, Pinto YM, Creemers EE. RNA splicing: regulation and dysregulation in the heart. Circ. Res. 2016;118:454-468.

     Not in our library10.1161/circresaha.115.307872

157. 157.

     Fochi S, et al. The emerging role of the RBM20 and PTBP1 ribonucleoproteins in heart development and cardiovascular diseases. Genes. 2020;11:402.

     Not in our library10.3390/genes11040402

158. 158.

     Liu H, et al. Endothelial deletion of PTBP1 disrupts ventricular chamber development. Nat. Commun. 2023;14:1796.

     Not in our library10.1038/s41467-023-37409-9

159. 159.

     Lu SH, et al. Alternative splicing mediated by RNA-binding protein RBM24 facilitates cardiac myofibrillogenesis in a differentiation stage-specific manner. Circ. Res. 2022;130:112-129.

     Not in our library10.1161/circresaha.121.320080

160. 160.

     Akerberg AA, et al. RBPMS2 is a myocardial-enriched splicing regulator required for cardiac function. Circ. Res. 2022;131:980-1000.

     Not in our library10.1161/circresaha.122.321728

161. 161.

     Chen X, et al. QKI is a critical pre-mRNA alternative splicing regulator of cardiac myofibrillogenesis and contractile function. Nat. Commun. 2021;12:89.

     Not in our library10.1038/s41467-020-20327-5

162. 162.

     Zhao Y, et al. Cardiomyocyte-specific long noncoding RNA regulates alternative splicing of the triadin gene in the heart. Circulation. 2022;146:699-714.

     Not in our library10.1161/circulationaha.121.058017

163. 163.

     Farina NH, et al. A role for RNA post-transcriptional regulation in satellite cell activation. Skelet. Muscle. 2012;2:21.

     Not in our library10.1186/2044-5040-2-21

164. 164.

     Bowman TV, et al. Differential mRNA processing in hematopoietic stem cells. Stem Cells. 2006;24:662-670.

     Not in our library10.1634/stemcells.2005-0552

165. 165.

     Park JW, Fu S, Huang B, Xu RH. Alternative splicing in mesenchymal stem cell differentiation. Stem Cells. 2020;38:1229-1240.

     Not in our library10.1002/stem.3248

166. 166.

     Yamazaki T, et al. TCF3 alternative splicing controlled by hnRNP H/F regulates E-cadherin expression and hESC pluripotency. Genes Dev. 2018;32:1161-1174.

     Not in our library10.1101/gad.316984.118

167. 167.

     Yamazaki T, Liu L, Manley JL. TCF3 mutually exclusive alternative splicing is controlled by long-range cooperative actions between hnRNPH1 and PTBP1. Rna. 2019;25:1497-1508.

     Not in our library10.1261/rna.072298.119

168. 168.

     de Morree A, Rando TA. Regulation of adult stem cell quiescence and its functions in the maintenance of tissue integrity. Nat. Rev. Mol. Cell Biol. 2023;24:334-354.

     Not in our library10.1038/s41580-022-00568-6

169. 169.

     Hayakawa-Yano Y, et al. An RNA-binding protein, Qki5, regulates embryonic neural stem cells through pre-mRNA processing in cell adhesion signaling. Gene Dev. 2017;31:1910-1925.

     Not in our library10.1101/gad.300822.117

170. 170.

     Chen XY, et al. QKI is a critical pre-mRNA alternative splicing regulator of cardiac myofibrillogenesis and contractile function. Nat. Commun. 2021;12:89.

     Not in our library10.1038/s41467-020-20327-5

171. 171.

     Neumann DP, Goodall GJ, Gregory PA. The Quaking RNA-binding proteins as regulators of cell differentiation. Wiley Interdiscip. Rev. RNA. 2022;13:e1724.

     Not in our library10.1002/wrna.1724

172. 172.

     Yang J, et al. RBM24 is a major regulator of muscle-specific alternative splicing. Dev. Cell. 2014;31:87-99.

     Not in our library10.1016/j.devcel.2014.08.025

173. 173.

     Fumagalli S, Totty NF, Hsuan JJ, Courtneidge SA. A target for Src in mitosis. Nature. 1994;368:871-874.

     Not in our library10.1038/368871a0

174. 174.

     Rekad Z, et al. Coalescent RNA-localizing and transcriptional activities of SAM68 modulate adhesion and subendothelial basement membrane assembly. eLife. 2023;12:e85165.

     Not in our library10.7554/elife.85165

175. 175.

     Song J, Richard S. Sam68 regulates S6K1 alternative splicing during adipogenesis. Mol. Cell Biol. 2015;35:1926-1939.

     Not in our library10.1128/mcb.01488-14

176. 176.

     Chao Y, et al. Regulatory roles and mechanisms of alternative RNA splicing in adipogenesis and human metabolic health. Cell Biosci. 2021;11:66.

     Not in our library10.1186/s13578-021-00581-w

177. 177.

     Zhang P, et al. RNA-binding proteins in the regulation of adipogenesis and adipose function. Cells. 2022;11:2357.

     Not in our library10.3390/cells11152357

178. 178.

     Peng L, et al. New insights into transcriptome variation during cattle adipocyte adipogenesis by direct RNA sequencing. iScience. 2023;26:107753.

     Not in our library10.1016/j.isci.2023.107753

179. 179.

     Fidalgo MF, et al. Aerocyte specification and lung adaptation to breathing is dependent on alternative splicing changes. Life Sci. Alliance. 2022;5:e202201554.

     Not in our library10.26508/lsa.202201554

180. 180.

     Wiegel, D., Dammann, C. E. L. & Nielsen, H. C. ErbB4 alternative splicing mediates fetal mouse alveolar type II cell differentiation in vitro. Pediatr. Res. (2022).

     Not in our library10.1038/s41390-022-02013-y

181. 181.

     Kedzierska H, Piekielko-Witkowska A. Splicing factors of SR and hnRNP families as regulators of apoptosis in cancer. Cancer Lett. 2017;396:53-65.

     Not in our library10.1016/j.canlet.2017.03.013

182. 182.

     Xu H, et al. Emerging roles of hnRNP A2B1 in cancer and inflammation. Int. J. Biol. Macromol. 2022;221:1077-1092.

     Not in our library10.1016/j.ijbiomac.2022.09.104

183. 183.

     Zhu W, et al. Roles of PTBP1 in alternative splicing, glycolysis, and oncogensis. J. Zhejiang Univ. Sci. B. 2020;21:122-136.

     Not in our library10.1631/jzus.b1900422

184. 184.

     Gallardo M, et al. Aberrant hnRNP K expression: all roads lead to cancer. Cell Cycle. 2016;15:1552-1557.

     Not in our library10.1080/15384101.2016.1164372

185. 185.

     Cerasuolo A, Buonaguro L, Buonaguro FM, Tornesello ML. The role of RNA splicing factors in cancer: regulation of viral and human gene expression in human papillomavirus-related cervical cancer. Front. Cell Dev. Biol. 2020;8:474.

     Not in our library10.3389/fcell.2020.00474

186. 186.

     Obeng EA, Stewart C, Abdel-Wahab O. Altered RNA processing in cancer pathogenesis and therapy. Cancer Discov. 2019;9:1493-1510.

     Not in our library10.1158/2159-8290.cd-19-0399

187. 187.

     McCutcheon IE, et al. Expression of the splicing regulator polypyrimidine tract-binding protein in normal and neoplastic brain. Neuro Oncol. 2004;6:9-14.

     Not in our library10.1215/s1152851703000279

188. 188.

     Manke MC, et al. ANXA7 regulates platelet lipid metabolism and Ca(2+) release in arterial thrombosis. Circ. Res. 2021;129:494-507.

     Not in our library10.1161/circresaha.121.319207

189. 189.

     Ferrarese R, et al. Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. J. Clin. Investig. 2014;124:2861-2876.

     Not in our library10.1172/jci68836

190. 190.
     EGF receptor trafficking: consequences for signaling and cancer · 2014

     No notice
191. 191.

     White ZB, et al. Impact of ANXA7 I1 expression on PDGFRA and MET endosomal trafficking in glioblastoma. Int. J. Radiat. Oncol. 2019;105:E683-E683.

     Not in our library10.1016/j.ijrobp.2019.06.1009

192. 192.
     Nogo-B is a key mediator of hepatic ischemia and reperfusion injury · 2020

     Not checked
193. 193.

     Mashtalir N, et al. A structural model of the endogenous human BAF complex informs disease mechanisms. Cell. 2020;183:802-817.e824.

     Not in our library10.1016/j.cell.2020.09.051

194. 194.
     Chromatin Remodeling BAF (SWI/SNF) Complexes in Neural Development and Disorders · 2017

     No notice
195. 195.

     Aldave G, et al. The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma. Neuro Oncol. 2018;20:930-941.

     Not in our library10.1093/neuonc/noy007

196. 196.

     Moroni RF, et al. Distinct expression pattern of microtubule-associated protein/microtubule affinity-regulating kinase 4 in differentiated neurons. Neuroscience. 2006;143:83-94.

     Not in our library10.1016/j.neuroscience.2006.07.052

197. 197.

     Rovina D, et al. Microtubule-associated protein/microtubule affinity-regulating kinase 4 (MARK4) plays a role in cell cycle progression and cytoskeletal dynamics. Eur. J. Cell Biol. 2014;93:355-365.

     Not in our library10.1016/j.ejcb.2014.07.004

198. 198.

     Wang K, et al. PTBP1 knockdown promotes neural differentiation of glioblastoma cells through UNC5B receptor. Theranostics. 2022;12:3847-3861.

     Not in our library10.7150/thno.71100

199. 199.

     Golan-Gerstl R, et al. Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res. 2011;71:4464-4472.

     Not in our library10.1158/0008-5472.can-10-4410

200. 200.

     Deng JM, et al. Effects of hnRNP A2/B1 knockdown on inhibition of glioblastoma cell invasion, growth and survival. Mol. Neurobiol. 2016;53:1132-1144.

     Not in our library10.1007/s12035-014-9080-3

201. 201.

     Yin DC, Kong CX, Chen MH. Effect of hnRNPA2/B1 on the proliferation and apoptosis of glioma U251 cells via the regulation of AKT and STAT3 pathways. Biosci. Rep. 2020;40:BSR20190318.

     Not in our library10.1042/bsr20190318

202. 202.

     Fabian C, Han M, Bjerkvig R, Niclou SP. Novel facets of glioma invasion. Int. Rev. Cell Mol. Biol. 2021;360:33-64.

     Not in our library10.1016/bs.ircmb.2020.08.001

203. 203.

     Decorsiere A, Cayrel A, Vagner S, Millevoi S. Essential role for the interaction between hnRNP H/F and a G quadruplex in maintaining p53 pre-mRNA 3’-end processing and function during DNA damage. Genes Dev. 2011;25:220-225.

     Not in our library10.1101/gad.607011

204. 204.

     Lefave CV, et al. Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J. 2011;30:4084-4097.

     Not in our library10.1038/emboj.2011.259

205. 205.

     Le Bras M, et al. Translational regulation by hnRNP H/F is essential for the proliferation and survival of glioblastoma. Cancers. 2022;14:1283.

     Not in our library10.3390/cancers14051283

206. 206.

     Zhou X, et al. Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B. J. Clin. Investig. 2019;129:676-693.

     Not in our library10.1172/jci120279

207. 207.

     Liu H, et al. SRPK1/2 and PP1alpha exert opposite functions by modulating SRSF1-guided MKNK2 alternative splicing in colon adenocarcinoma. J. Exp. Clin. Cancer Res. 2021;40:75.

     Not in our library10.1186/s13046-021-01877-y

208. 208.
     Mnk2 Alternative Splicing Modulates the p38-MAPK Pathway and Impacts Ras-Induced Transformation · 2014

     Not checked
209. 209.

     Mogilevsky M, et al. Modulation of MKNK2 alternative splicing by splice-switching oligonucleotides as a novel approach for glioblastoma treatment. Nucleic Acids Res. 2018;46:11396-11404.

     Not in our library10.1093/nar/gky921

210. 210.

     Song X, et al. SRSF3-regulated RNA alternative splicing promotes glioblastoma tumorigenicity by affecting multiple cellular processes. Cancer Res. 2019;79:5288-5301.

     Not in our library10.1158/0008-5472.can-19-1504

211. 211.

     Vikhreva P, Melino G, Amelio I. p73 alternative splicing: exploring a biological role for the C-terminal isoforms. J. Mol. Biol. 2018;430:1829-1838.

     Not in our library10.1016/j.jmb.2018.04.034

212. 212.

     Fuentes-Fayos AC, et al. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3. Brain. 2020;143:3273-3293.

     Not in our library10.1093/brain/awaa273

213. 213.
     The Apoptosis Paradox in Cancer · 2022

     No notice
214. 214.

     Bugg D, et al. MBNL1 drives dynamic transitions between fibroblasts and myofibroblasts in cardiac wound healing. Cell Stem Cell. 2022;29:419-433 e410.

     Not in our library10.1016/j.stem.2022.01.012

215. 215.

     Fernandez-Costa JM, Llamusi MB, Garcia-Lopez A, Artero R. Alternative splicing regulation by muscleblind proteins: from development to disease. Biol. Rev. 2011;86:947-958.

     Not in our library10.1111/j.1469-185x.2011.00180.x

216. 216.

     Gates DP, Coonrod LA, Berglund JA. Autoregulated splicing of muscleblind-like 1 (MBNL1) Pre-mRNA. J. Biol. Chem. 2011;286:34224-34233.

     Not in our library10.1074/jbc.m111.236547

217. 217.

     Konieczny P, et al. Autoregulation of MBNL1 function by exon 1 exclusion from MBNL1 transcript. Nucleic Acids Res. 2017;45:1760-1775.

     Not in our library10.1093/nar/gkw1158

218. 218.

     Voss DM, et al. The alternative splicing factor, MBNL1, inhibits glioblastoma tumor initiation and progression by reducing hypoxia-induced stemness. Cancer Res. 2020;80:4681-4692.

     Not in our library10.1158/0008-5472.can-20-1233

219. 219.

     Xie Y, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369-379.

     Not in our library10.1038/cdd.2015.158

220. 220.

     Sun S, et al. RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m(6)A-dependent manner. Cell Death Dis. 2022;13:73.

     Not in our library10.1038/s41419-022-04524-2

221. 221.

     Wang X, et al. Targeting the splicing factor NONO inhibits GBM progression through GPX1 intron retention. Theranostics. 2022;12:5451-5469.

     Not in our library10.7150/thno.72248

222. 222.

     Zhang M, et al. Axonogenesis is coordinated by neuron-specific alternative splicing programming and splicing regulator PTBP2. Neuron. 2019;101:690-706 e610.

     Not in our library10.1016/j.neuron.2019.01.022

223. 223.

     Zhao L, et al. Comprehensive characterization of alternative mRNA splicing events in glioblastoma: implications for prognosis, molecular subtypes, and immune microenvironment remodeling. Front. Oncol. 2020;10:555632.

     Not in our library10.3389/fonc.2020.555632

224. 224.

     Szklener K, et al. New directions in the therapy of glioblastoma. Cancers. 2022;14:5377.

     Not in our library10.3390/cancers14215377

225. 225.

     Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J. Clin. 2021;71:7-33.

     Not in our library10.3322/caac.21654

226. 226.

     Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389:1134-1150.

     Not in our library10.1016/s0140-6736(16)31891-8

227. 227.

     Yu S, et al. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer. J. Transl. Med. 2020;18:286.

     Not in our library10.1186/s12967-020-02454-1

228. 228.

     Yang Q, et al. Aberrant alternative splicing in breast cancer. J. Mol. Cell Biol. 2019;11:920-929.

     Not in our library10.1093/jmcb/mjz033

229. 229.

     Liu Z, et al. Hypoxia-induced suppression of alternative splicing of MBD2 promotes breast cancer metastasis via activation of FZD1. Cancer Res. 2021;81:1265-1278.

     Not in our library10.1158/0008-5472.can-20-2876

230. 230.
     c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment · 2023

     No notice
231. 231.
     Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1 · 2021

     Not checked
232. 232.

     Deng L, et al. MYC-driven U2SURP regulates alternative splicing of SAT1 to promote triple-negative breast cancer progression. Cancer Lett. 2023;560:216124.

     Not in our library10.1016/j.canlet.2023.216124

233. 233.

     Yu Y, Fang L. CircRPAP2 regulates the alternative splicing of PTK2 by binding to SRSF1 in breast cancer. Cell Death Discov. 2022;8:152.

     Not in our library10.1038/s41420-022-00965-y

234. 234.

     Wang S, et al. High-throughput chemical screening identifies focal adhesion kinase and aurora kinase B inhibition as a synergistic treatment combination in Ewing sarcoma. Clin. Cancer Res. 2019;25:4552-4566.

     Not in our library10.1158/1078-0432.ccr-17-0375

235. 235.

     Fan T, et al. Bit1 knockdown contributes to growth suppression as well as the decreases of migration and invasion abilities in esophageal squamous cell carcinoma via suppressing FAK-paxillin pathway. Mol. Cancer. 2016;15:23.

     Not in our library10.1186/s12943-016-0507-5

236. 236.

     Fish L, et al. A prometastatic splicing program regulated by SNRPA1 interactions with structured RNA elements. Science. 2021;372:eabc7531.

     Not in our library10.1126/science.abc7531

237. 237.
     HNRNPU promotes the progression of triple-negative breast cancer via RNA transcription and alternative splicing mechanisms · 2022

     Not checked
238. 238.

     Zhou L, et al. Monocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction. Circ. Res. 2006;98:1177-1185.

     Not in our library10.1161/01.res.0000220106.64661.71

239. 239.
     MCPIP1-mediated NFIC alternative splicing inhibits proliferation of triple-negative breast cancer via cyclin D1-Rb-E2F1 axis · 2021

     Not checked
240. 240.

     Yang J, et al. LIN28A modulates splicing and gene expression programs in breast cancer cells. Mol. Cell Biol. 2015;35:3225-3243.

     Not in our library10.1128/mcb.00426-15

241. 241.

     Kim SJ, et al. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. Theranostics. 2020;10:7974-7992.

     Not in our library10.7150/thno.45037

242. 242.

     Iino K, et al. RNA-binding protein NONO promotes breast cancer proliferation by post-transcriptional regulation of SKP2 and E2F8. Cancer Sci. 2020;111:148-159.

     Not in our library10.1111/cas.14240

243. 243.

     Naro C, et al. The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells. J. Exp. Clin. Cancer Res. 2021;40:397.

     Not in our library10.1186/s13046-021-02210-3

244. 244.

     Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharm. Rev. 2012;64:706-721.

     Not in our library10.1124/pr.111.005637

245. 245.

     Gokmen-Polar Y, et al. Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways. EMBO Rep. 2019;20:e46078.

     Not in our library10.15252/embr.201846078

246. 246.

     Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer. 2002;2:101-112.

     Not in our library10.1038/nrc721

247. 247.

     Xu Y, et al. ERalpha is an RNA-binding protein sustaining tumor cell survival and drug resistance. Cell. 2021;184:5215-5229.e5217.

     Not in our library10.1016/j.cell.2021.08.036

248. 248.

     Elhasnaoui J, et al. The estrogen receptor alpha signaling pathway controls alternative splicing in the absence of ligands in breast cancer cells. Cancers. 2021;13:6261.

     Not in our library10.3390/cancers13246261

249. 249.

     Wang C, et al. SRPK1 acetylation modulates alternative splicing to regulate cisplatin resistance in breast cancer cells. Commun. Biol. 2020;3:268.

     Not in our library10.1038/s42003-020-0983-4

250. 250.

     Choudhary C, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325:834-840.

     Not in our library10.1126/science.1175371

251. 251.
     The Construction of Bone Metastasis-Specific Prognostic Model and Co-expressed Network of Alternative Splicing in Breast Cancer · 2020

     Not checked
252. 252.

     Coomer AO, et al. Alternative splicing in lung cancer. Biochim Biophys. Acta Gene Regul. Mech. 2019;1862:194388.

     Not in our library10.1016/j.bbagrm.2019.05.006

253. 253.

     Liu J, et al. Prognostic alternative splicing events related splicing factors define the tumor microenvironment and pharmacogenomic landscape in lung adenocarcinoma. Aging. 2022;14:6689-6715.

     Not in our library10.18632/aging.204244

254. 254.

     Wu Q, et al. Multi-omics analysis reveals RNA splicing alterations and their biological and clinical implications in lung adenocarcinoma. Signal Transduct. Target Ther. 2022;7:270.

     Not in our library10.1038/s41392-022-01098-5

255. 255.

     de Miguel FJ, et al. A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer. Mol. Oncol. 2016;10:1437-1449.

     Not in our library10.1016/j.molonc.2016.08.001

256. 256.

     Cao Y, et al. RBM10 regulates tumor apoptosis, proliferation, and metastasis. Front. Oncol. 2021;11:603932.

     Not in our library10.3389/fonc.2021.603932

257. 257.

     Wang JZ, et al. QKI-5 regulates the alternative splicing of cytoskeletal gene ADD3 in lung cancer. J. Mol. Cell Biol. 2021;13:347-360.

     Not in our library10.1093/jmcb/mjaa063

258. 258.

     Zhu S, et al. SAM68 promotes tumorigenesis in lung adenocarcinoma by regulating metabolic conversion via PKM alternative splicing. Theranostics. 2021;11:3359-3375.

     Not in our library10.7150/thno.51360

259. 259.

     Jamal-Hanjani M, et al. Tracking the evolution of non-small-cell lung cancer. New Engl. J. Med. 2017;376:2109-2121.

     Not in our library10.1056/nejmoa1616288

260. 260.

     Zhao J, et al. Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing. Sci. Rep. 2017;7:40488.

     Not in our library10.1038/srep40488

261. 261.
     SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer · 2021

     Not checked
262. 262.

     Nanjo S, et al. Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. J. Clin. Investig. 2022;132:e145099.

     Not in our library10.1172/jci145099

263. 263.

     Zhang S, et al. RNA binding motif protein 10 suppresses lung cancer progression by controlling alternative splicing of eukaryotic translation initiation factor 4H. EBioMedicine. 2020;61:103067.

     Not in our library10.1016/j.ebiom.2020.103067

264. 264.

     Truitt ML, Ruggero D. New frontiers in translational control of the cancer genome (vol 16, pg 288, 2016). Nat. Rev. Cancer. 2017;17:332-332.

     Not in our library10.1038/nrc.2017.30

265. 265.
     Nuclear Aurora kinase A switches m6A reader YTHDC1 to enhance an oncogenic RNA splicing of tumor suppressor RBM4 · 2022

     Not checked
266. 266.

     Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394-424.

     Not in our library10.3322/caac.21492

267. 267.
     Medical management of gastric cancer: a 2017 update · 2017

     No notice
268. 268.

     Feng H, et al. Identification and validation of critical alternative splicing events and splicing factors in gastric cancer progression. J. Cell Mol. Med. 2020;24:12667-12680.

     Not in our library10.1111/jcmm.15835

269. 269.

     Jun Y, et al. Comprehensive analysis of alternative splicing in gastric cancer identifies epithelial-mesenchymal transition subtypes associated with survival. Cancer Res. 2022;82:543-555.

     Not in our library10.1158/0008-5472.can-21-2117

270. 270.
     LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM · 2021

     No notice
271. 271.

     Di Matteo A, et al. Alternative splicing changes promoted by NOVA2 upregulation in endothelial cells and relevance for gastric cancer. Int. J. Mol. Sci. 2023;24:8102.

     Not in our library10.3390/ijms24098102

272. 272.

     Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J. Clin. 2017;67:7-30.

     Not in our library10.3322/caac.21387

273. 273.
     ESRP1-regulated isoform switching of LRRFIP2 determines metastasis of gastric cancer · 2022

     Not checked
274. 274.

     He Q, et al. LINC00924-induced fatty acid metabolic reprogramming facilitates gastric cancer peritoneal metastasis via hnRNPC-regulated alternative splicing of Mnk2. Cell Death Dis. 2022;13:987.

     Not in our library10.1038/s41419-022-05436-x

275. 275.

     Liang X, et al. PTBP3 contributes to the metastasis of gastric cancer by mediating CAV1 alternative splicing. Cell Death Dis. 2018;9:569.

     Not in our library10.1038/s41419-018-0608-8

276. 276.

     Wang X, et al. CircURI1 interacts with hnRNPM to inhibit metastasis by modulating alternative splicing in gastric cancer. Proc. Natl. Acad. Sci. USA. 2021;118:e2012881118.

     Not in our library10.1073/pnas.2012881118

277. 277.

     Lee SCW, et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins (vol 22, pg 672, 2016). Nat. Med. 2016;22:692-692.

     Not in our library10.1038/nm0616-692d

278. 278.

     Yoshimi A, Abdel-Wahab O. Molecular pathways: understanding and targeting mutant spliceosomal proteins. Clin. Cancer Res. 2017;23:336-341.

     Not in our library10.1158/1078-0432.ccr-16-0131

279. 279.

     Yoshimi A, et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature. 2019;574:273-277.

     Not in our library10.1038/s41586-019-1618-0

280. 280.

     Inoue D, et al. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature. 2019;574:432-436.

     Not in our library10.1038/s41586-019-1646-9

281. 281.

     Lee SC, et al. Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations. Cancer Cell. 2018;34:225-241.e228.

     Not in our library10.1016/j.ccell.2018.07.003

282. 282.
     RNA binding proteins in MLL-rearranged leukemia · 2022

     Not checked
283. 283.

     Hodson DJ, Screen M, Turner M. RNA-binding proteins in hematopoiesis and hematological malignancy. Blood. 2019;133:2365-2373.

     Not in our library10.1182/blood-2018-10-839985

284. 284.
     ‘Acute myeloid leukemia: a comprehensive review and 2016 update’ · 2016

     No notice
285. 285.

     Al-Harbi S, et al. An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1. Blood Adv. 2020;4:229-238.

     Not in our library10.1182/bloodadvances.2019000168

286. 286.

     Mandoli A, et al. The hematopoietic transcription factors RUNX1 and ERG prevent AML1-ETO oncogene overexpression and onset of the apoptosis program in t(8;21) AMLs. Cell Rep. 2016;17:2087-2100.

     Not in our library10.1016/j.celrep.2016.08.082

287. 287.

     Trombly DJ, et al. Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells. BMC Genomics. 2015;16:309.

     Not in our library10.1186/s12864-015-1445-0

288. 288.

     Grinev VV, et al. RUNX1/RUNX1T1 mediates alternative splicing and reorganises the transcriptional landscape in leukemia. Nat. Commun. 2021;12:520.

     Not in our library10.1038/s41467-020-20848-z

289. 289.

     Rivera OD, et al. Alternative splicing redefines landscape of commonly mutated genes in acute myeloid leukemia. Proc. Natl. Acad. Sci. USA. 2021;118:e2014967118.

     Not in our library10.1073/pnas.2014967118

290. 290.

     Radzisheuskaya A, et al. PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia. Nat. Struct. Mol. Biol. 2019;26:999-1012.

     Not in our library10.1038/s41594-019-0313-z

291. 291.

     Wang E, et al. Targeting an RNA-binding protein network in acute myeloid leukemia. Cancer Cell. 2019;35:369-384.e367.

     Not in our library10.1016/j.ccell.2019.01.010

292. 292.

     Waldman T. Emerging themes in cohesin cancer biology. Nat. Rev. Cancer. 2020;20:504-515.

     Not in our library10.1038/s41568-020-0270-1

293. 293.

     Singh AK, et al. Cohesin regulates alternative splicing. Sci. Adv. 2023;9:eade3876.

     Not in our library10.1126/sciadv.ade3876

294. 294.

     Yang YT, et al. Evaluation of the clinical significance of global mRNA alternative splicing in patients with acute myeloid leukemia. Am. J. Hematol. 2023;98:784-793.

     Not in our library10.1002/ajh.26893

295. 295.

     Wang E, et al. Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia. Cancer Cell. 2023;41:164-180.e168.

     Not in our library10.1016/j.ccell.2022.12.002

296. 296.

     Wei Y, et al. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013;27:1832-1840.

     Not in our library10.1038/leu.2013.180

297. 297.

     Zhao HG, Deininger M. Always stressed but never exhausted: how stem cells in myeloid neoplasms avoid extinction in inflammatory conditions. Blood. 2023;141:2797-2812.

     Not in our library10.1182/blood.2022017152

298. 298.

     Florian MC, et al. Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. Cell Stem Cell. 2012;10:520-530.

     Not in our library10.1016/j.stem.2012.04.007

299. 299.

     Fang J, et al. Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. Nat. Immunol. 2017;18:236-245.

     Not in our library10.1038/ni.3654

300. 300.

     Zhou Y, et al. Posttranslational regulation of the exon skipping machinery controls aberrant splicing in leukemia. Cancer Discov. 2020;10:1388-1409.

     Not in our library10.1158/2159-8290.cd-19-1436

301. 301.

     Schmitz R, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116-120.

     Not in our library10.1038/nature11378

302. 302.

     Yamazaki T, Liu LZ, Conlon EG, Manley JL. Burkitt lymphoma-related TCF3 mutations alter TCF3 alternative splicing by disrupting hnRNPH1 binding. Rna Biol. 2020;17:1383-1390.

     Not in our library10.1080/15476286.2020.1772559

303. 303.

     Orlando EJ, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat. Med. 2018;24:1504-1506.

     Not in our library10.1038/s41591-018-0146-z

304. 304.

     Roberts KG. Genetics and prognosis of ALL in children vs adults. Hematol.-Am. Soc. Hematol. 2018;2018:137-145.

     Not in our library10.1182/asheducation-2018.1.137

305. 305.

     Zhao YQ, et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. 2021;137:471-484.

     Not in our library10.1182/blood.2020006287

306. 306.
     Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy · 2021

     No notice
307. 307.

     Bagashev A, et al. CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum. Mol. Cell Biol. 2018;38:e00383-18.

     Not in our library10.1128/mcb.00383-18

308. 308.

     Sotillo E, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282-1295.

     Not in our library10.1158/2159-8290.cd-15-1020

309. 309.

     Asnani M, et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia. 2020;34:1202-1207.

     Not in our library10.1038/s41375-019-0580-z

310. 310.
     High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance · 2022

     Not checked
311. 311.

     Shinohara H, et al. Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells. Cancer Lett. 2016;371:1-11.

     Not in our library10.1016/j.canlet.2015.11.020

312. 312.

     Chang AJ, Autio KA, Roach M, Scher HI. High-risk prostate cancer-classification and therapy. Nat. Rev. Clin. Oncol. 2014;11:308-323.

     Not in our library10.1038/nrclinonc.2014.68

313. 313.

     Munkley J, Livermore K, Rajan P, Elliott DJ. RNA splicing and splicing regulator changes in prostate cancer pathology. Hum. Genet. 2017;136:1143-1154.

     Not in our library10.1007/s00439-017-1792-9

314. 314.

     Marima R, et al. MicroRNA and alternative mRNA splicing events in cancer drug response/resistance: potent therapeutic targets. Biomedicines. 2021;9:1818.

     Not in our library10.3390/biomedicines9121818

315. 315.

     Wach S, Taubert H, Cronauer M. Role of androgen receptor splice variants, their clinical relevance and treatment options. World J. Urol. 2020;38:647-656.

     Not in our library10.1007/s00345-018-02619-0

316. 316.

     Rebello RJ, et al. Prostate cancer. Nat. Rev. Dis. Prim. 2021;7:9.

     Not in our library10.1038/s41572-020-00243-0

317. 317.

     Del Giudice M, et al. FOXA1 regulates alternative splicing in prostate cancer. Cell Rep. 2022;40:111404.

     Not in our library10.1016/j.celrep.2022.111404

318. 318.

     Urbanski L, et al. MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors. Cell Rep. 2022;41:111704.

     Not in our library10.1016/j.celrep.2022.111704

319. 319.

     Koh CM, et al. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature. 2015;523:96-100.

     Not in our library10.1038/nature14351

320. 320.

     Phillips JW, et al. Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers. Proc. Natl. Acad. Sci. USA. 2020;117:5269-5279.

     Not in our library10.1073/pnas.1915975117

321. 321.

     Chen X, et al. The RNA-binding proteins hnRNP H and F regulate splicing of a MYC-dependent HRAS exon in prostate cancer cells. Proc. Natl. Acad. Sci. USA. 2023;120:e2220190120.

     Not in our library10.1073/pnas.2220190120

322. 322.
     Profiling PRMT methylome reveals roles of hnRNPA1 arginine methylation in RNA splicing and cell growth · 2021

     No notice
323. 323.

     Labrecque MP, et al. RNA splicing factors SRRM3 and SRRM4 distinguish molecular phenotypes of castration-resistant neuroendocrine prostate cancer. Cancer Res. 2021;81:4736-4750.

     Not in our library10.1158/0008-5472.can-21-0307

324. 324.

     Zhang W, et al. The bone microenvironment invigorates metastatic seeds for further dissemination. Cell. 2021;184:2471-2486.e2420.

     Not in our library10.1016/j.cell.2021.03.011

325. 325.

     Zeng Y, et al. Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing. Cancer Res. 2013;73:4123-4133.

     Not in our library10.1158/0008-5472.can-12-1343

326. 326.

     Zhang S, et al. RBM3 suppresses stemness remodeling of prostate cancer in bone microenvironment by modulating N6-methyladenosine on CTNNB1 mRNA. Cell Death Dis. 2023;14:91.

     Not in our library10.1038/s41419-023-05627-0

327. 327.

     Tripathi V, et al. Direct regulation of alternative splicing by SMAD3 through PCBP1 is essential to the tumor-promoting role of TGF-beta. Mol. Cell. 2016;64:549-564.

     Not in our library10.1016/j.molcel.2016.09.013

328. 328.

     Chen Q, et al. TGF-beta1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44. Cell Mol. Life Sci. 2021;78:949-962.

     Not in our library10.1007/s00018-020-03544-5

329. 329.

     Fabris L, et al. The potential of microRNAs as prostate cancer biomarkers. Eur. Urol. 2016;70:312-322.

     Not in our library10.1016/j.eururo.2015.12.054

330. 330.

     Paschalis A, et al. Alternative splicing in prostate cancer. Nat. Rev. Clin. Oncol. 2018;15:663-675.

     Not in our library10.1038/s41571-018-0085-0

331. 331.

     Liu LL, et al. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene. 2014;33:3140-3150.

     Not in our library10.1038/onc.2013.284

332. 332.

     Lu Y, et al. Emerging pharmacotherapeutic strategies to overcome undruggable proteins in cancer. Int. J. Biol. Sci. 2023;19:3360-3382.

     Not in our library10.7150/ijbs.83026

333. 333.

     Chou FJ, et al. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer. Cell Death Dis. 2020;11:942.

     Not in our library10.1038/s41419-020-02970-4

334. 334.

     Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl. Oncol. 2021;14:101174.

     Not in our library10.1016/j.tranon.2021.101174

335. 335.
     Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m6A-mediated degradation of STEAP3 mRNA · 2022

     No notice
336. 336.
     Hypoxia induced LUCAT1/PTBP1 axis modulates cancer cell viability and chemotherapy response · 2020

     No notice
337. 337.

     Mochizuki Y, et al. Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer. Int. J. Cancer. 2021;149:1787-1800.

     Not in our library10.1002/ijc.33758

338. 338.

     Liu W, et al. Comprehensive analysis of RNA-binding protein SRSF2-dependent alternative splicing signature in malignant proliferation of colorectal carcinoma. J. Biol. Chem. 2023;299:102876.

     Not in our library10.1016/j.jbc.2023.102876

339. 339.

     Wan L, et al. SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. Gut. 2019;68:118-129.

     Not in our library10.1136/gutjnl-2017-314983

340. 340.

     Han F, et al. GLTSCR1 coordinates alternative splicing and transcription elongation of ZO1 to regulate colorectal cancer progression. J. Mol. Cell Biol. 2022;14:mjac009.

     Not in our library10.1093/jmcb/mjac009

341. 341.

     Zhao S, et al. Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer. Br. J. Cancer. 2023;128:665-677.

     Not in our library10.1038/s41416-022-02077-x

342. 342.

     Zhou X, et al. BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells. Nat. Commun. 2014;5:4581.

     Not in our library10.1038/ncomms5581

343. 343.

     Pan YJ, et al. Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer. Clin. Transl. Med. 2022;12:e1113.

     Not in our library10.1002/ctm2.1113

344. 344.

     Tam BY, et al. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. Cancer Lett. 2020;473:186-197.

     Not in our library10.1016/j.canlet.2019.09.009

345. 345.

     Hellborg F, et al. Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein. Oncogene. 2001;20:5466-5474.

     Not in our library10.1038/sj.onc.1204722

346. 346.

     Fearon ER. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 2011;6:479-507.

     Not in our library10.1146/annurev-pathol-011110-130235

347. 347.

     Janic A, et al. DNA repair processes are critical mediators of p53-dependent tumor suppression. Nat. Med. 2018;24:947-953.

     Not in our library10.1038/s41591-018-0043-5

348. 348.

     Muys BR, et al. The p53-induced RNA-binding protein ZMAT3 is a splicing regulator that inhibits the splicing of oncogenic CD44 variants in colorectal carcinoma. Genes Dev. 2021;35:102-116.

     Not in our library10.1101/gad.342634.120

349. 349.

     Muys BR, et al. Matrin3 regulates mitotic spindle dynamics by controlling alternative splicing of CDC14B. Cell Rep. 2023;42:112260.

     Not in our library10.1016/j.celrep.2023.112260

350. 350.

     Ueda J, et al. Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases. Oncogene. 2014;33:4485-4495.

     Not in our library10.1038/onc.2013.392

351. 351.

     Cheng DK, et al. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer. Proc. Natl. Acad. Sci. USA. 2021;118:e2016904118.

     Not in our library10.1073/pnas.2016904118

352. 352.

     Baer JM, et al. Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. Nat. Immunol. 2023;24:1443-1457.

     Not in our library10.1038/s41590-023-01579-x

353. 353.

     Wan L, et al. Splicing factor SRSF1 promotes pancreatitis and KRASG12D-mediated pancreatic cancer. Cancer Discov. 2023;13:1678-1695.

     Not in our library10.1158/2159-8290.cd-22-1013

354. 354.
     Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop · 2022

     Not checked
355. 355.

     Biffi G, et al. IL1-induced JAK/STAT signaling is antagonized by TGFbeta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9:282-301.

     Not in our library10.1158/2159-8290.cd-18-0710

356. 356.

     Jones S, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806.

     Not in our library10.1126/science.1164368

357. 357.

     Jbara A, et al. RBFOX2 modulates a metastatic signature of alternative splicing in pancreatic cancer. Nature. 2023;617:147-153.

     Not in our library10.1038/s41586-023-05820-3

358. 358.

     Huang XT, et al. HNRNPC impedes m(6)A-dependent anti-metastatic alternative splicing events in pancreatic ductal adenocarcinoma. Cancer Lett. 2021;518:196-206.

     Not in our library10.1016/j.canlet.2021.07.016

359. 359.

     Yang G, et al. Integrative genomic analysis of gemcitabine resistance in pancreatic cancer by patient-derived xenograft models. Clin. Cancer Res. 2021;27:3383-3396.

     Not in our library10.1158/1078-0432.ccr-19-3975

360. 360.

     Calabretta S, et al. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene. 2016;35:2031-2039.

     Not in our library10.1038/onc.2015.270

361. 361.

     Wang P, et al. Targeted regulation of Rell2 by microRNA-18a is implicated in the anti-metastatic effect of polyphyllin VI in breast cancer cells. Eur. J. Pharm. 2019;851:161-173.

     Not in our library10.1016/j.ejphar.2019.02.041

362. 362.

     Li Z, et al. DHX38 restricts chemoresistance by regulating the alternative pre-mRNA splicing of RELL2 in pancreatic ductal adenocarcinoma. PLoS Genet. 2023;19:e1010847.

     Not in our library10.1371/journal.pgen.1010847

363. 363.

     Tian JB, et al. Aberrant RNA splicing is a primary link between genetic variation and pancreatic cancer risk. Cancer Res. 2022;82:2084-2096.

     Not in our library10.1158/0008-5472.can-21-4367

364. 364.

     Xia CF, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin. Med. J. 2022;135:584-590.

     Not in our library10.1097/cm9.0000000000002108

365. 365.

     Li X, et al. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat. Rev. Cancer. 2021;21:541-557.

     Not in our library10.1038/s41568-021-00383-9

366. 366.

     Huang S, et al. PCBP1 regulates the transcription and alternative splicing of metastasis‑related genes and pathways in hepatocellular carcinoma. Sci. Rep. 2021;11:23356.

     Not in our library10.1038/s41598-021-02642-z

367. 367.
     Alternative splicing and cancer: a systematic review · 2021

     No notice
368. 368.

     Caruso S, Nault JC. A dive into the deep heterogeneity of hepatocellular carcinoma. Gastroenterology. 2019;157:1477-1479.

     Not in our library10.1053/j.gastro.2019.10.003

369. 369.

     Lee SE, Alcedo KP, Kim HJ, Snider NT. Alternative splicing in hepatocellular carcinoma. Cell Mol. Gastroenterol. Hepatol. 2020;10:699-712.

     Not in our library10.1016/j.jcmgh.2020.04.018

370. 370.

     Chen H, et al. Long-read RNA sequencing identifies alternative splice variants in hepatocellular carcinoma and tumor-specific isoforms. Hepatology. 2019;70:1011-1025.

     Not in our library10.1002/hep.30500

371. 371.

     Luo C, et al. SRSF2 regulates alternative splicing to drive hepatocellular carcinoma development. Cancer Res. 2017;77:1168-1178.

     Not in our library10.1158/0008-5472.can-16-1919

372. 372.

     Liu L, et al. HBV enhances sorafenib resistance in hepatocellular carcinoma by reducing ferroptosis via SRSF2-mediated abnormal PCLAF splicing. Int. J. Mol. Sci. 2023;24:3263.

     Not in our library10.3390/ijms24043263

373. 373.

     Chang C, et al. The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma. Nat. Commun. 2022;13:1363.

     Not in our library10.1038/s41467-022-29016-x

374. 374.

     Sen S, Langiewicz M, Jumaa H, Webster NJ. Deletion of serine/arginine-rich splicing factor 3 in hepatocytes predisposes to hepatocellular carcinoma in mice. Hepatology. 2015;61:171-183.

     Not in our library10.1002/hep.27380

375. 375.

     Chen D, et al. PPM1G promotes the progression of hepatocellular carcinoma via phosphorylation regulation of alternative splicing protein SRSF3. Cell Death Dis. 2021;12:722.

     Not in our library10.1038/s41419-021-04013-y

376. 376.

     Wang H, et al. A coiled-coil domain containing 50 splice variant is modulated by serine/arginine-rich splicing factor 3 and promotes hepatocellular carcinoma in mice by the Ras signaling pathway. Hepatology. 2019;69:179-195.

     Not in our library10.1002/hep.30147

377. 377.

     Liu X, et al. SRSF10 stabilizes CDC25A by triggering exon 6 skipping to promote hepatocarcinogenesis. J. Exp. Clin. Cancer Res. 2022;41:353.

     Not in our library10.1186/s13046-022-02558-0

378. 378.

     Shilo A, et al. Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development. RNA. 2014;20:505-515.

     Not in our library10.1261/rna.042259.113

379. 379.

     Zhou ZJ, et al. HNRNPAB induces epithelial-mesenchymal transition and promotes metastasis of hepatocellular carcinoma by transcriptionally activating SNAIL. Cancer Res. 2014;74:2750-2762.

     Not in our library10.1158/0008-5472.can-13-2509

380. 380.

     Wang H, et al. Long noncoding RNA miR503HG, a prognostic indicator, inhibits tumor metastasis by regulating the HNRNPA2B1/NF-kappaB pathway in hepatocellular carcinoma. Theranostics. 2018;8:2814-2829.

     Not in our library10.7150/thno.23012

381. 381.

     Shen L, et al. Skipping of exon 10 in Axl pre-mRNA regulated by PTBP1 mediates invasion and metastasis process of liver cancer cells. Theranostics. 2020;10:5719-5735.

     Not in our library10.7150/thno.42010

382. 382.

     Yu L, et al. MTR4 drives liver tumorigenesis by promoting cancer metabolic switch through alternative splicing. Nat. Commun. 2020;11:708.

     Not in our library10.1038/s41467-020-14437-3

383. 383.

     Liu D, et al. HNRNPC downregulation inhibits IL-6/STAT3-mediated HCC metastasis by decreasing HIF1A expression. Cancer Sci. 2022;113:3347-3361.

     Not in our library10.1111/cas.15494

384. 384.
     Targeting HNRNPM Inhibits Cancer Stemness and Enhances Antitumor Immunity in Wnt-activated Hepatocellular CarcinomaSummary · 2022

     Not checked
385. 385.

     Li SL, et al. Transcriptome-wide analysis reveals the landscape of aberrant alternative splicing events in liver cancer. Hepatology. 2019;69:359-375.

     Not in our library10.1002/hep.30158

386. 386.

     Qiao Y, et al. RNA binding protein RALY activates the cholesterol synthesis pathway through an MTA1 splicing switch in hepatocellular carcinoma. Cancer Lett. 2022;538:215711.

     Not in our library10.1016/j.canlet.2022.215711

387. 387.

     Sohail M, Xie JY. Evolutionary emergence of a novel splice variant with an opposite effect on the cell cycle. Mol. Cell Biol. 2015;35:2203-2214.

     Not in our library10.1128/mcb.00190-15

388. 388.

     Wen C, et al. SRSF3 and HNRNPH1 regulate radiation-induced alternative splicing of protein arginine methyltransferase 5 in hepatocellular carcinoma. Int. J. Mol. Sci. 2022;23:14832.

     Not in our library10.3390/ijms232314832

389. 389.

     Hu Z, et al. Splicing regulator p54(nrb)/non-POU domain-containing octamer-binding protein enhances carcinogenesis through oncogenic isoform switch of MYC Box-dependent interacting protein 1 in hepatocellular carcinoma. Hepatology. 2020;72:548-568.

     Not in our library10.1002/hep.31062

390. 390.

     Kahles A, et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell. 2018;34:211-224.e216.

     Not in our library10.1016/j.ccell.2018.07.001

391. 391.

     Ajiro M, et al. A genome landscape of SRSF3-regulated splicing events and gene expression in human osteosarcoma U2OS cells. Nucleic Acids Res. 2016;44:1854-1870.

     Not in our library10.1093/nar/gkv1500

392. 392.

     Jia R, et al. Oncogenic splicing factor SRSF3 regulates ILF3 alternative splicing to promote cancer cell proliferation and transformation. RNA. 2019;25:630-644.

     Not in our library10.1261/rna.068619.118

393. 393.

     Zhang S, et al. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Lett. 2016;371:214-224.

     Not in our library10.1016/j.canlet.2015.11.045

394. 394.

     Slansky JE, Spellman PT. Alternative splicing in tumors—a path to immunogenicity? New Engl. J. Med. 2019;380:877-880.

     Not in our library10.1056/nejmcibr1814237

395. 395.

     Bonnal SC, Lopez-Oreja I, Valcarcel J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat. Rev. Clin. Oncol. 2020;17:457-474.

     Not in our library10.1038/s41571-020-0350-x

396. 396.

     Desterro J, Bak-Gordon P, Carmo-Fonseca M. Targeting mRNA processing as an anticancer strategy. Nat. Rev. Drug Discov. 2020;19:112-129.

     Not in our library10.1038/s41573-019-0042-3

397. 397.

     Kalev P, et al. MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage. Cancer Cell. 2021;39:209-224.e211.

     Not in our library10.1016/j.ccell.2020.12.010

398. 398.

     Poulard C, et al. Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERalpha(+) breast cancer. EMBO Mol. Med. 2023;15:e17248.

     Not in our library10.15252/emmm.202217248

399. 399.

     Banasavadi-Siddegowda YK, et al. PRMT5 as a druggable target for glioblastoma therapy. Neuro Oncol. 2018;20:753-763.

     Not in our library10.1093/neuonc/nox206

400. 400.

     Braun CJ, et al. Coordinated Splicing Of Regulatory Detained Introns Within Oncogenic Transcripts Creates An Exploitable Vulnerability In Malignant Glioma. Cancer Cell. 2017;32:411-426.e411.

     Not in our library10.1016/j.ccell.2017.08.018

401. 401.

     Seufert L, Benzing T, Ignarski M, Muller RU. RNA-binding proteins and their role in kidney disease. Nat. Rev. Nephrol. 2022;18:153-170.

     Not in our library10.1038/s41581-021-00497-1

402. 402.

     Low YH, Asi Y, Foti SC, Lashley T. Heterogeneous nuclear ribonucleoproteins: implications in neurological diseases. Mol. Neurobiol. 2021;58:631-646.

     Not in our library10.1007/s12035-020-02137-4

403. 403.

     Krach F, et al. Aberrant NOVA1 function disrupts alternative splicing in early stages of amyotrophic lateral sclerosis. Acta Neuropathol. 2022;144:413-435.

     Not in our library10.1007/s00401-022-02450-3

404. 404.

     Neumann M, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137-149.

     Not in our library10.1007/s00401-008-0477-9

405. 405.
     Dysregulation of Translation in TDP-43 Proteinopathies: Deficits in the RNA Supply Chain and Local Protein Production · 2022

     Not checked
406. 406.

     MacNair L, et al. MTHFSD and DDX58 are novel RNA-binding proteins abnormally regulated in amyotrophic lateral sclerosis. Brain. 2016;139:86-100.

     Not in our library10.1093/brain/awv308

407. 407.

     Martinez FJ, et al. Protein-RNA networks regulated by normal and ALS-associated mutant HNRNPA2B1 in the nervous system. Neuron. 2016;92:780-795.

     Not in our library10.1016/j.neuron.2016.09.050

408. 408.

     Scheltens P, et al. Alzheimer’s disease. Lancet. 2021;397:1577-1590.

     Not in our library10.1016/s0140-6736(20)32205-4

409. 409.

     Gu J, et al. Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: Implications for the pathogenesis of tauopathies. J. Biol. Chem. 2017;292:10600-10612.

     Not in our library10.1074/jbc.m117.783498

410. 410.

     van Bergeijk P, et al. SRSF1 and PTBP1 are trans-acting factors that suppress the formation of a CD33 splicing isoform linked to Alzheimer’s disease risk. Mol. Cell Biol. 2019;39:e00568-18.

     Not in our library10.1128/mcb.00568-18

411. 411.
     Nuclear speckle specific hnRNP D-like prevents age- and AD-related cognitive decline by modulating RNA splicing · 2021

     Not checked
412. 412.

     Bhatnagar A, et al. Tip60’s novel RNA-Binding function modulates alternative splicing of pre-mRNA targets implicated in Alzheimer’s disease. J. Neurosci. 2023;43:2398-2423.

     Not in our library10.1523/jneurosci.2331-22.2023

413. 413.

     Tabrizi SJ, et al. Potential disease-modifying therapies for Huntington’s disease: lessons learned and future opportunities. Lancet Neurol. 2022;21:645-658.

     Not in our library10.1016/s1474-4422(22)00121-1

414. 414.

     Elorza A, et al. Huntington’s disease-specific mis-splicing unveils key effector genes and altered splicing factors. Brain. 2021;144:2009-2023.

     Not in our library10.1093/brain/awab087

415. 415.

     Li D, Yu W, Lai M. Towards understandings of serine/arginine-rich splicing factors. Acta Pharm. Sin. B. 2023;13:3181-3207.

     Not in our library10.1016/j.apsb.2023.05.022

416. 416.

     Ibanez-Costa A, et al. Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy. Ann. Rheum. Dis. 2022;81:56-67.

     Not in our library10.1136/annrheumdis-2021-220308

417. 417.

     Ren P, et al. Alternative splicing: a new cause and potential therapeutic target in autoimmune disease. Front. Immunol. 2021;12:713540.

     Not in our library10.3389/fimmu.2021.713540

418. 418.

     Wang J, et al. SpliceDisease database: linking RNA splicing and disease. Nucleic Acids Res. 2012;40:D1055-D1059.

     Not in our library10.1093/nar/gkr1171

419. 419.

     Monteuuis G, et al. The changing paradigm of intron retention: regulation, ramifications and recipes. Nucleic Acids Res. 2019;47:11497-11513.

     Not in our library10.1093/nar/gkz1068

420. 420.

     Ingelfinger JR, Jarcho JA. Increase in the incidence of diabetes and its implications. New Engl. J. Med. 2017;376:1473-1474.

     Not in our library10.1056/nejme1616575

421. 421.

     Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol. 2018;14:88-98.

     Not in our library10.1038/nrendo.2017.151

422. 422.

     Chen X, et al. Advances in the study of RNA-binding proteins in diabetic complications. Mol. Metab. 2022;62:101515.

     Not in our library10.1016/j.molmet.2022.101515

423. 423.

     Nutter CA, Kuyumcu-Martinez MN. Emerging roles of RNA-binding proteins in diabetes and their therapeutic potential in diabetic complications. Wiley Interdiscip. Rev. RNA. 2018;9:e85036.

     Not in our library10.1002/wrna.1459

424. 424.

     Alvelos MI, et al. When one becomes many-Alternative splicing in beta-cell function and failure. Diabetes Obes. Metab. 2018;20:77-87.

     Not in our library10.1111/dom.13388

425. 425.

     Ravanidis S, Kattan FG, Doxakis E. Unraveling the pathways to neuronal homeostasis and disease: mechanistic insights into the role of RNA-binding proteins and associated factors. Int. J. Mol. Sci. 2018;19:2280.

     Not in our library10.3390/ijms19082280

426. 426.

     Marcheva B, et al. A role for alternative splicing in circadian control of exocytosis and glucose homeostasis. Genes Dev. 2020;34:1089-1105.

     Not in our library10.1101/gad.338178.120

427. 427.

     McCartney CR, Marshall JC. CLINICAL PRACTICE. Polycystic ovary syndrome. New Engl. J. Med. 2016;375:54-64.

     Not in our library10.1056/nejmcp1514916

428. 428.

     Wang F, et al. Alternative splicing of the androgen receptor in polycystic ovary syndrome. Proc. Natl. Acad. Sci. USA. 2015;112:4743-4748.

     Not in our library10.1073/pnas.1418216112

429. 429.

     Younossi Z, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69:2672-2682.

     Not in our library10.1002/hep.30251

430. 430.

     Del Rio-Moreno M, et al. Dysregulation of the splicing machinery is associated to the development of nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2019;104:3389-3402.

     Not in our library10.1210/jc.2019-00021

431. 431.

     Kumar D, et al. Degradation of splicing factor SRSF3 contributes to progressive liver disease. J. Clin. Investig. 2019;129:4477-4491.

     Not in our library10.1172/jci127374

432. 432.

     Zhang Z, et al. Hepatic HuR modulates lipid homeostasis in response to high-fat diet. Nat. Commun. 2020;11:3067.

     Not in our library10.1038/s41467-020-16918-x

433. 433.

     Li Y, et al. DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing. Cell Metab. 2021;33:2004-2020.e2009.

     Not in our library10.1016/j.cmet.2021.09.008

434. 434.

     Hyun J, et al. Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease. J. Hepatol. 2021;75:623-633.

     Not in our library10.1016/j.jhep.2021.04.033

435. 435.

     Soussan P, et al. Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. J. Infect. Dis. 2008;198:218-225.

     Not in our library10.1086/589623

436. 436.

     Duriez M, et al. Alternative splicing of hepatitis B virus: a novel virus/host interaction altering liver immunity. J. Hepatol. 2017;67:687-699.

     Not in our library10.1016/j.jhep.2017.05.025

437. 437.

     de Bruin RG, Rabelink TJ, van Zonneveld AJ, van der Veer EP. Emerging roles for RNA-binding proteins as effectors and regulators of cardiovascular disease. Eur. Heart J. 2017;38:1380-1388.

     Not in our library10.1093/eurheartj/ehw567

438. 438.

     Liu J, et al. RNA binding protein 24 deletion disrupts global alternative splicing and causes dilated cardiomyopathy. Protein Cell. 2019;10:405-416.

     Not in our library10.1007/s13238-018-0578-8

439. 439.

     Gan P, et al. RBPMS is an RNA-binding protein that mediates cardiomyocyte binucleation and cardiovascular development. Dev. Cell. 2022;57:959-973.e957.

     Not in our library10.1016/j.devcel.2022.03.017

440. 440.

     Paronetto MP, Passacantilli I, Sette C. Alternative splicing and cell survival: from tissue homeostasis to disease. Cell Death Differ. 2016;23:1919-1929.

     Not in our library10.1038/cdd.2016.91

441. 441.

     Agosto LM, Lynch KW. Alternative pre-mRNA splicing switch controls hESC pluripotency and differentiation. Genes Dev. 2018;32:1103-1104.

     Not in our library10.1101/gad.318451.118

442. 442.

     Yuan S, Norgard RJ, Stanger BZ. Cellular plasticity in cancer. Cancer Discov. 2019;9:837-851.

     Not in our library10.1158/2159-8290.cd-19-0015

443. 443.

     Leclair NK, et al. Poison exon splicing regulates a coordinated network of SR protein expression during differentiation and tumorigenesis. Mol. Cell. 2020;80:648-665.e649.

     Not in our library10.1016/j.molcel.2020.10.019

444. 444.
     Auto-regulatory feedback by RNA-binding proteins · 2019

     No notice
445. 445.

     Zhao Z, et al. QKI shuttles internal m(7)G-modified transcripts into stress granules and modulates mRNA metabolism. Cell. 2023;186:3208-3226.e3227.

     Not in our library10.1016/j.cell.2023.05.047

446. 446.

     Simmler P, et al. Mutant SF3B1 promotes malignancy in PDAC. eLife. 2023;12:e80683.

     Not in our library10.7554/elife.80683

447. 447.

     Zhang J, et al. Disease-causing mutations in SF3B1 alter splicing by disrupting interaction with SUGP1. Mol. Cell. 2019;76:82-95.e87.

     Not in our library10.1016/j.molcel.2019.07.017

448. 448.

     Shuai S, et al. The U1 spliceosomal RNA is recurrently mutated in multiple cancers. Nature. 2019;574:712-716.

     Not in our library10.1038/s41586-019-1651-z

449. 449.

     Bowling EA, et al. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell. 2021;184:384-403.e321.

     Not in our library10.1016/j.cell.2020.12.031

450. 450.

     Ziegenhain C, et al. Comparative analysis of single-cell RNA sequencing methods. Mol. Cell. 2017;65:631-643.e634.

     Not in our library10.1016/j.molcel.2017.01.023

451. 451.

     Ardui S, Ameur A, Vermeesch JR, Hestand MS. Single molecule real-time (SMRT) sequencing comes of age: applications and utilities for medical diagnostics. Nucleic Acids Res. 2018;46:2159-2168.

     Not in our library10.1093/nar/gky066

452. 452.

     Liao L, et al. Lysine 2-hydroxyisobutyrylation of NAT10 promotes cancer metastasis in an ac4C-dependent manner. Cell Res. 2023;33:355-371.

     Not in our library10.1038/s41422-023-00793-4

453. 453.
     RNA structure probing reveals the structural basis of Dicer binding and cleavage · 2021

     Not checked
454. 454.

     Wan Y, Qu K, Ouyang Z, Chang HY. Genome-wide mapping of RNA structure using nuclease digestion and high-throughput sequencing. Nat. Protoc. 2013;8:849-869.

     Not in our library10.1038/nprot.2013.045

455. 455.

     Mehta M, Raguraman R, Ramesh R, Munshi A. RNA binding proteins (RBPs) and their role in DNA damage and radiation response in cancer. Adv. Drug Deliv. Rev. 2022;191:114569.

     Not in our library10.1016/j.addr.2022.114569

456. 456.
     The midnolin-proteasome pathway catches proteins for ubiquitination-independent degradation · 2023

     No notice
457. 457.

     Rossi G, Manfrin A, Lutolf MP. Progress and potential in organoid research. Nat. Rev. Genet. 2018;19:671-687.

     Not in our library10.1038/s41576-018-0051-9

458. 458.
     Advances in COVID-19 mRNA vaccine development · 2022

     No notice
459. 459.
     mRNA vaccine: a potential therapeutic strategy · 2021

     No notice
460. 460.

     Warzecha CC, et al. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol. Cell. 2009;33:591-601.

     Not in our library10.1016/j.molcel.2009.01.025

461. 461.

     Burguera D, et al. Evolutionary recruitment of flexible Esrp-dependent splicing programs into diverse embryonic morphogenetic processes. Nat. Commun. 2017;8:1799.

     Not in our library10.1038/s41467-017-01961-y

462. 462.

     Derham JM, Kalsotra A. The discovery, function, and regulation of epithelial splicing regulatory proteins (ESRP) 1 and 2. Biochem. Soc. Trans. 2023;51:1097-1109.

     Not in our library10.1042/bst20221124

463. 463.

     Pai TP, et al. Drosophila ORB protein in two mushroom body output neurons is necessary for long-term memory formation. Proc. Natl. Acad. Sci. USA. 2013;110:7898-7903.

     Not in our library10.1073/pnas.1216336110

464. 464.

     Lantz V, Ambrosio L, Schedl P. The Drosophila orb gene is predicted to encode sex-specific germline RNA-binding proteins and has localized transcripts in ovaries and early embryos. Development. 1992;115:75-88.

     Not in our library10.1242/dev.115.1.75

465. 465.
     The role of CPEB family proteins in the nervous system function in the norm and pathology · 2021

     Not checked
466. 466.

     Huang YS, Kan MC, Lin CL, Richter JD. CPEB3 and CPEB4 in neurons: analysis of RNA-binding specificity and translational control of AMPA receptor GluR2 mRNA. EMBO J. 2006;25:4865-4876.

     Not in our library10.1038/sj.emboj.7601322

467. 467.

     Fernandez-Miranda G, Mendez R. The CPEB-family of proteins, translational control in senescence and cancer. Ageing Res. Rev. 2012;11:460-472.

     Not in our library10.1016/j.arr.2012.03.004

468. 468.

     Lachiondo-Ortega S, et al. Hu antigen R (HuR) protein structure, function and regulation in hepatobiliary tumors. Cancers. 2022;14:2666.

     Not in our library10.3390/cancers14112666

469. 469.

     Majumder M, et al. HuR as a molecular target for cancer therapeutics and immune-related disorders. Adv. Drug Deliv. Rev. 2022;188:114442.

     Not in our library10.1016/j.addr.2022.114442

470. 470.
     The hnRNP family: insights into their role in health and disease · 2016

     No notice
471. 471.

     Yisraeli JK. VICKZ proteins: a multi-talented family of regulatory RNA-binding proteins. Biol. Cell. 2005;97:87-96.

     Not in our library10.1042/bc20040151

472. 472.

     Zhu TY, Hong LL, Ling ZQ. Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential. Biomark. Res. 2023;11:62.

     Not in our library10.1186/s40364-023-00499-0

473. 473.

     Ramesh-Kumar D, Guil S. The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer. Semin. Cancer Biol. 2022;86:18-31.

     Not in our library10.1016/j.semcancer.2022.05.009

474. 474.

     Gheldof A, et al. Evolutionary functional analysis and molecular regulation of the ZEB transcription factors. Cell Mol. Life Sci. 2012;69:2527-2541.

     Not in our library10.1007/s00018-012-0935-3

475. 475.

     Verstappen G, et al. Atypical Mowat-Wilson patient confirms the importance of the novel association between ZFHX1B/SIP1 and NuRD corepressor complex. Hum. Mol. Genet. 2008;17:1175-1183.

     Not in our library10.1093/hmg/ddn007

476. 476.

     Scott CL, Omilusik KD. ZEBs: novel players in immune cell development and function. Trends Immunol. 2019;40:431-446.

     Not in our library10.1016/j.it.2019.03.001

477. 477.

     Li H, et al. Zinc finger E-box binding homeobox 1 and atherosclerosis: new insights and therapeutic potential. J. Cell Physiol. 2021;236:4216-4230.

     Not in our library10.1002/jcp.30177

478. 478.

     Briata P, et al. Diverse roles of the nucleic acid-binding protein KHSRP in cell differentiation and disease. Wiley Interdiscip. Rev. RNA. 2016;7:227-240.

     Not in our library10.1002/wrna.1327

479. 479.

     Patel P, et al. Intra-axonal translation of Khsrp mRNA slows axon regeneration by destabilizing localized mRNAs. Nucleic Acids Res. 2022;50:5772-5792.

     Not in our library10.1093/nar/gkac337

480. 480.

     Stavraka C, Blagden S. The La-related proteins, a family with connections to cancer. Biomolecules. 2015;5:2701-2722.

     Not in our library10.3390/biom5042701

481. 481.

     Lizarrondo J, Dock-Bregeon AC, Martino L, Conte MR. Structural dynamics in the La-module of La-related proteins. Rna Biol. 2021;18:194-206.

     Not in our library10.1080/15476286.2020.1733799

482. 482.

     Maraia RJ, Mattijssen S, Cruz-Gallardo I, Conte MR. The La and related RNA-binding proteins (LARPs): structures, functions, and evolving perspectives. Wiley Interdiscip. Rev. RNA. 2017;8:e6832.

     Not in our library10.1002/wrna.1430

483. 483.

     Shyh-Chang N, Daley GQ. Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell. 2013;12:395-406.

     Not in our library10.1016/j.stem.2013.03.005

484. 484.

     Kudinov AE, Karanicolas J, Golemis EA, Boumber Y. Musashi RNA-binding proteins as cancer drivers and novel therapeutic targets. Clin. Cancer Res. 2017;23:2143-2153.

     Not in our library10.1158/1078-0432.ccr-16-2728

485. 485.

     Smialek MJ, Ilaslan E, Sajek MP, Jaruzelska J. Role of PUM RNA-binding proteins in cancer. Cancers. 2021;13:129.

     Not in our library10.3390/cancers13010129

486. 486.

     Li Z, et al. The RNA-binding motif protein family in cancer: friend or foe? Front. Oncol. 2021;11:757135.

     Not in our library10.3389/fonc.2021.757135

487. 487.

     Sutherland LC, Rintala-Maki ND, White RD, Morin CD. RNA binding motif (RBM) proteins: a novel family of apoptosis modulators? J. Cell Biochem. 2005;94:5-24.

     Not in our library10.1002/jcb.20204

488. 488.

     Sanchez-Jimenez F, Sanchez-Margalet V. Role of Sam68 in post-transcriptional gene regulation. Int. J. Mol. Sci. 2013;14:23402-23419.

     Not in our library10.3390/ijms141223402

489. 489.

     Fernandez-Gomez A, Izquierdo JM. The multifunctional faces of T-cell intracellular antigen 1 in health and disease. Int. J. Mol. Sci. 2022;23:1400.

     Not in our library10.3390/ijms23031400

490. 490.

     Velasco BR, Izquierdo JM. T-cell intracellular antigen 1-like protein in physiology and pathology. Int. J. Mol. Sci. 2022;23:7836.

     Not in our library10.3390/ijms23147836

491. 491.

     Guo AX, Cui JJ, Wang LY, Yin JY. The role of CSDE1 in translational reprogramming and human diseases. Cell Commun. Signal. 2020;18:14.

     Not in our library10.1186/s12964-019-0496-2

492. 492.

     Carabet LA, et al. Computer-aided discovery of small molecules targeting the RNA splicing activity of hnRNP A1 in castration-resistant prostate cancer. Molecules. 2019;24:763.

     Not in our library10.3390/molecules24040763

493. 493.

     Supradit K, et al. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis. Toxicol. Vitr. 2022;82:105385.

     Not in our library10.1016/j.tiv.2022.105385

494. 494.

     Han T, et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science. 2017;356:eaal3755.

     Not in our library10.1126/science.aal3755

495. 495.

     Marcel V, et al. Modulation of p53beta and p53gamma expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death Differ. 2014;21:1377-1387.

     Not in our library10.1038/cdd.2014.73

496. 496.

     Sako Y, et al. Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy. Sci. Rep. 2017;7:46126.

     Not in our library10.1038/srep46126

497. 497.

     Salvador F, Gomis RR. CLK2 blockade modulates alternative splicing compromising MYC-driven breast tumors. EMBO Mol. Med. 2018;10:e9213.

     Not in our library10.15252/emmm.201809213

498. 498.

     Chu WH, et al. Discovery of tetrahydroisoquinolineindole derivatives as first dual PRMT5 inhibitors/hnRNP E1 upregulators: design, synthesis and biological evaluation. Eur. J. Med. Chem. 2023;258:115625.

     Not in our library10.1016/j.ejmech.2023.115625

499. 499.

     Datta A, et al. Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells. Cancer Lett. 2017;408:73-81.

     Not in our library10.1016/j.canlet.2017.08.020

500. 500.

     Benavides-Serrato A, et al. Repurposing potential of riluzole as an ITAF inhibitor in mTOR therapy resistant glioblastoma. Int. J. Mol. Sci. 2020;21:344.

     Not in our library10.3390/ijms21010344

501. 501.

     Meng N, et al. Novel role of heterogeneous nuclear ribonucleoprotein E1 in regulation of apoptosis and autophagy by a triazole derivative in vascular endothelial cells. Int. J. Biol. Sci. 2019;15:1299-1309.

     Not in our library10.7150/ijbs.32677

502. 502.

     Shorrock HK, Gillingwater TH, Groen EJN. Overview of current drugs and molecules in development for spinal muscular atrophy therapy. Drugs. 2018;78:293-305.

     Not in our library10.1007/s40265-018-0868-8

503. 503.

     Bondu S, et al. A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome. Sci. Transl. Med. 2019;11:eaav5467.

     Not in our library10.1126/scitranslmed.aav5467

504. 504.

     Leivonen SK, et al. Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma. Blood Cancer J. 2017;7:e596.

     Not in our library10.1038/bcj.2017.71

505. 505.

     Brander DM, et al. SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia. Br. J. Haematol. 2019;184:605-615.

     Not in our library10.1111/bjh.15677

506. 506.

     Moulton VR, Gillooly AR, Tsokos GC. Ubiquitination regulates expression of the serine/arginine-rich splicing factor 1 (SRSF1) in normal and systemic lupus erythematosus (SLE) T cells. J. Biol. Chem. 2014;289:4126-4134.

     Not in our library10.1074/jbc.m113.518662

507. 507.

     Kletzl H, et al. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: results from trials in healthy adults and patients with spinal muscular atrophy. Neuromuscul. Disord. 2019;29:21-29.

     Not in our library10.1016/j.nmd.2018.10.001

508. 508.

     Seiler M, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat. Med. 2018;24:497-504.

     Not in our library10.1038/nm.4493

509. 509.

     Krach F, et al. An alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington’s disease patient neurons. Nat. Commun. 2022;13:6797.

     Not in our library10.1038/s41467-022-34419-x

510. 510.

     Ratni H, et al. Specific correction of alternative survival motor neuron 2 splicing by small molecules: discovery of a potential novel medicine to treat spinal muscular atrophy. J. Med. Chem. 2016;59:6086-6100.

     Not in our library10.1021/acs.jmedchem.6b00459

511. 511.

     Yoda A, et al. CTX-712, a novel Clk inhibitor targeting myeloid neoplasms with SRSF2 mutation. Blood. 2021;138:205-205.

     Not in our library10.1182/blood-2021-148205

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.